<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001332" GROUP_ID="MS" ID="968200050715472404" MERGED_FROM="" MODIFIED="2008-09-18 10:13:17 +0200" MODIFIED_BY="Liliana Coco" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-09-11 11:18:15 +0200" MODIFIED_BY="Liliana Coco">
<TITLE>Anti-spasticity agents for multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="14874" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shakespeare</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Neurological Rehabilitation Medicine</POSITION>
<EMAIL_1>david.shakespeare@lthtr.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neuro-rehabilitation Unit</DEPARTMENT>
<ORGANISATION>Lancashire Teaching Hospitals Trust</ORGANISATION>
<ADDRESS_1>32A Watling Street Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Preston</CITY>
<ZIP>PR2 8DY</ZIP>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-01772 524771</PHONE_1>
<PHONE_2/>
<FAX_1>+44-01772 524504</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-09-11 11:18:15 +0200" MODIFIED_BY="Liliana Coco">
<PERSON ID="14874" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shakespeare</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Neurological Rehabilitation Medicine</POSITION>
<EMAIL_1>david.shakespeare@lthtr.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neuro-rehabilitation Unit</DEPARTMENT>
<ORGANISATION>Lancashire Teaching Hospitals Trust</ORGANISATION>
<ADDRESS_1>32A Watling Street Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Preston</CITY>
<ZIP>PR2 8DY</ZIP>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-01772 524771</PHONE_1>
<PHONE_2/>
<FAX_1>+44-01772 524504</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7209" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Mike</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Boggild</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>boggild.m@wcnn-tr.nwest.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Walton Centre for Neurology &amp; Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 525 5719</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 529 5500</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14882" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carolyn</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Young</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist</POSITION>
<EMAIL_1>Carolyn.Young@thewaltoncentre.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Walton Centre for Neurology &amp; Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-0151- 529 5711</PHONE_1>
<PHONE_2>+44-0151 529 5512</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-03 11:07:26 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="14" MONTH="7" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="10" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-07-01 11:37:29 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-01 11:34:49 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="30" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-07-03 11:06:56 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-03 11:06:56 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="1" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Searches were re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-03 11:06:51 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="1" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-01 11:34:53 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="15" MONTH="6" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-01 11:35:13 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="15" MONTH="6" YEAR="2001"/>
<DESCRIPTION>
<P>Searches were-re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-11 11:25:37 +0200" MODIFIED_BY="Liliana Coco">
<SUMMARY MODIFIED="2008-07-01 11:47:01 +0200" MODIFIED_BY="Liliana Coco">
<TITLE MODIFIED="2008-07-01 11:47:01 +0200" MODIFIED_BY="Liliana Coco">The effect of anti-spasticity agents in people with multiple sclerosis</TITLE>
<SUMMARY_BODY>
<P>Multiple sclerosis (MS) is a chronic disease of the nervous system which affects young and middle-aged adults. Spasticity, a common problem in people with MS, is a disorder of voluntary movement caused by damage to the central nervous system. The main sign is the resistance to passive movement of a limb but other associated features - pain, spasms, loss of function - affect people's quality of life more directly. <BR/>Many anti-spasticity drugs are available but the review of trials found that there is not enough evidence to compare their effectiveness. <BR/>More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-26 12:47:17 +0200" MODIFIED_BY="Deirdre Beecher">
<ABS_BACKGROUND>
<P>Spasticity is a common problem in multiple sclerosis (MS) patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in MS patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-26 12:47:17 +0200" MODIFIED_BY="Deirdre Beecher">
<P>We searched the Cochrane MS Group trials register (June 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2003), MEDLINE (January 1966 to June 2003), EMBASE (January 1988 to June 2003), bibliographies of relevant articles, personal communication, manual searches of relevant journals and information from drug companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Double-blind, randomised controlled trials (either placebo-controlled or comparative studies) of at least seven days duration.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two independent reviewers extracted data and the findings of the trials were summarised. Missing data were collected by correspondence with principal investigators. A meta-analysis was not performed due to the inadequacy of outcome measures and methodological problems with the studies reviewed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty-six placebo-controlled studies (using baclofen, dantrolene, tizanidine, botulinum toxin, vigabatrin, prazepam, threonine and cannabinoids) and thirteen comparative studies met the selection criteria and were included in this review. Only fifteen of these studies used the Ashworth scale, of which only three of the eight placebo-controlled trials and none of the seven comparative studies showed a statistically significant difference between test drugs. Spasms, other symptoms and overall impressions were only assessed using unvalidated scores and results of functional assessments were inconclusive.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can be made to guide prescribing. The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-11 11:25:37 +0200" MODIFIED_BY="Liliana Coco">
<BACKGROUND MODIFIED="2008-08-22 09:59:59 +0200" MODIFIED_BY="Deirdre Beecher">
<P>Spasticity, defined as "a motor disorder characterised by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one component of the upper motor neuron syndrome" (<LINK REF="REF-Lance-1980" TYPE="REFERENCE">Lance 1980</LINK>), is a significant problem for about 60% of MS patients (<LINK REF="STD-Smith-1991" TYPE="STUDY">Smith 1991</LINK>). It reduces mobility, makes transfers more difficult, is associated with painful muscular spasms and weakness, and predisposes to the development of contractures.</P>
<P>Drugs such as baclofen, diazepam, dantrolene and tizanidine are frequently used in an attempt to reduce spasticity and many others have been reported to have some anti-spasticity effect. All of these have different modes of action and different side-effect profiles which can limit their usefulness. It is thus important to document the efficacy and tolerability of these agents in order to guide rational prescribing and suggest directions for future research into the management of this often difficult problem. </P>
<P>The only widely used method available to assess the degree of spasticity is clinical assessment using the ordinal Ashworth Scale (<LINK REF="REF-Ashworth-1964" TYPE="REFERENCE">Ashworth 1964</LINK>; <LINK REF="REF-Wade-1992" TYPE="REFERENCE">Wade 1992</LINK>), which allocates a score between one and four depending on the difficulty in passively moving the limb of a relaxed patient. However this does not distinguish reflex- from non-reflex mediated causes of resistance to movement (<LINK REF="REF-Perry-1993" TYPE="REFERENCE">Perry 1993</LINK>) and it bears no clear relation to functional impairment (which can clearly be affected by many other factors) or occurrence of painful muscle spasms. In addition, function can be aided to a certain degree by spasticity (for example, walking can be possible despite leg weakness if spasticity maintains the anti-gravity posture). Thus assessing the effect of spasticity on a patient (and thus the role of anti-spasticity treatment) requires the use of several outcome measures.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in MS patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-11 11:25:37 +0200" MODIFIED_BY="Liliana Coco">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Double-blind, randomised controlled trials (RCTs) of treatment duration longer than seven days which are either placebo-controlled or comparing two or more agents were analysed. Quasi-randomised, unrandomised and unblinded trials were excluded. Cross-over trials were included and the authors were contacted to obtain information about the results of each period of the study.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a clinically definite diagnosis of MS (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>) at any stage of their disease and with spasticity of any degree were included. Patients within one month of a relapse were excluded. Studies including patients with other diagnoses were excluded unless individual data for the MS patients could be obtained either from the published results or through contact with the authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Drug therapies reviewed were: baclofen (by oral or intra-thecal administration), diazepam, dantrolene, tizanidine, threonine, clonidine, 3,4-diaminopyridine, cyproheptadine, progabide, gabapentin, vigabatrin, oxcarbazepine, ketazolam, botulinum toxin and cannabinoids. Evidence for control for other factors which can affect spasticity (including use of other drugs (in particular benzodiazepines, anti-psychotic agents and anti-depressants), physiotherapy regimes, patients' mood, intercurrent and other illness) was sought.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>(1) Ashworth Scale (assessed double-blind)<BR/>(2) Functional assessment (using the Kurtzke Expanded Disability Status Scale (EDSS) (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>)<BR/>(3) Patient-reported functional status and muscle spasm frequency count<BR/>(4) Side-effect reports</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-11 11:25:37 +0200" MODIFIED_BY="Liliana Coco">
<ELECTRONIC_SEARCHES MODIFIED="2008-09-11 11:25:09 +0200" MODIFIED_BY="Liliana Coco">
<P>(1) We searched the Cochrane Multiple Sclerosis Group trials register (June 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) "The Cochrane Library, 2003, issue 2(<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (PubMed) (from 1966 to June 2003) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), using the search strategy for randomised controlled trials of Dickersin and Larson (<LINK REF="REF-Clarke-1995" TYPE="REFERENCE">Clarke 1995</LINK>), specifying the search for "spasticity" and "multiple sclerosis", and EMBASE (from 1988 to June 2003) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) using a similar strategy to that outlined for MEDLINE.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-11 11:25:31 +0200" MODIFIED_BY="Liliana Coco">
<P>(2) Searching reference lists from published reviews on symptom control in multiple sclerosis and identified RCTs.<BR/>(3) Personal communication with first authors of relevant trials or reviews, and other multiple sclerosis experts.<BR/>(4) Contacting drug manufacturers for baclofen (Novartis), dantrolene (Proctor and Gamble), tizanidine (Athena), gabapentin (Parke-Davis Medical), vigabatrin (Hoechst Marion Roussel), Botulinum toxin (Allergan &amp; Ipsen) and any other drugs identified in relevant RCTs.<BR/>(5) Manual searches of the following journals: Multiple Sclerosis, Archives of Physical Medicine and Rehabilitation.</P>
<P>Unpublished trials were identified using strategies 3 and 4 above.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two independent reviewers screened titles and abstracts of papers identified using the above strategies to identify studies which met previously-defined inclusion criteria. Agreement was reached by consensus, after assessment of the full text of the paper and contacting the authors for further information where necessary. Two reviewers then independently abstracted the patient and study characteristics (including dose regimes, length of trial and outcome measures used) and the outcomes (as defined above). Final results were reached by consensus.</P>
<P>The methodological quality of the studies was assessed paying particular attention to: whether patients were truly randomised to the study groups; whether patients, the health care team and spasticity assessors were blind to assigned therapy; whether the groups were truly identical in terms of stage of disease and pre-treatment spasticity level, progress of disease during the trial (e.g. number of relapses), other concomitant drug treatments, non-drug treatments for spasticity (e.g. physiotherapy regimes), assessment of spasticity and side-effects.<BR/>
<BR/>Analysis of outcomes was on an intention-to-treat basis. The first task of the review was to summarise evidence for the efficacy and tolerability of the different treatment regimens by documenting the change in Ashworth score, EDSS score, muscle spasm frequency count and side-effect reports in the study groups. Heterogeneity analyses were planned, comparing the log-odds-ratios for the Ashworth and EDSS scores calculated according to the proportional odds model (<LINK REF="REF-Whitehead-1994" TYPE="REFERENCE">Whitehead 1994</LINK>). </P>
<P>An attempt to carry out a meta-analysis of the Ashworth scale results was planned. As it is an ordinal scale, analysis of the individual patient data using a proportional odds model (<LINK REF="REF-Whitehead-1994" TYPE="REFERENCE">Whitehead 1994</LINK>) was thought to be more appropriate than simply treating it as if it were a continuous scale. Sensitivity analyses were planned to investigate the effect of methodological quality and severity of spasticity on the trial results. Results of the different periods of cross-over trials were included separately when available. Heterogeneity analyses were planned to investigate the effect of excluding all except the first treatment period of each cross-over study.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Thirty-nine of the 169 identified studies met the inclusion criteria (randomised, double-blind controlled trials of at least seven days duration).</P>
<P>
<B>(1) Oral baclofen versus placebo</B>
<BR/>Five crossover studies (<LINK REF="STD-Basmajian-1974" TYPE="STUDY">Basmajian 1974</LINK>; <LINK REF="STD-Basmajian-1975" TYPE="STUDY">Basmajian 1975</LINK>; <LINK REF="STD-Feldman-1978" TYPE="STUDY">Feldman 1978</LINK>; <LINK REF="STD-Sawa-1979" TYPE="STUDY">Sawa 1979</LINK>; <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK>) and one parallel-group study (<LINK REF="STD-Sachais-1977" TYPE="STUDY">Sachais 1977</LINK>) have been reviewed. The results of the study reported in <LINK REF="STD-Basmajian-1975" TYPE="STUDY">Basmajian 1975</LINK> included the participants previously reported in <LINK REF="STD-Basmajian-1974" TYPE="STUDY">Basmajian 1974</LINK>, as the two studies used identical methodology. Different daily doses of baclofen were used: three studies used 60 to 80 mg of baclofen, <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> used 20 mg, and Basmajian (<LINK REF="STD-Basmajian-1974" TYPE="STUDY">Basmajian 1974</LINK>; <LINK REF="STD-Basmajian-1975" TYPE="STUDY">Basmajian 1975</LINK>) titrated the dose according to effect (but the final dose used was not reported). <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> compared the effects of baclofen and placebo with and without a standardised programme of stretching exercises. Only <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> reported use of the Ashworth score.</P>
<P>
<B>(2) Dantrolene versus placebo</B>
<BR/>Three crossover trials (<LINK REF="STD-Gelenberg-1973" TYPE="STUDY">Gelenberg 1973</LINK>; <LINK REF="STD-Sheplan-1975" TYPE="STUDY">Sheplan 1975</LINK>; <LINK REF="STD-Luisto-1982" TYPE="STUDY">Luisto 1982</LINK>) and one parallel-group trial (<LINK REF="STD-Tolosa-1975" TYPE="STUDY">Tolosa 1975</LINK>) have been reviewed. No studies report using the Ashworth score.</P>
<P>
<B>(3) Tizanidine versus placebo</B>
<BR/>Three parallel-group trials have been reviewed (<LINK REF="STD-Lapierre-1987" TYPE="STUDY">Lapierre 1987</LINK>; <LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK>; <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>) using up to 36 mg tizanidine but only two reported use of the Ashworth scale (<LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK>; <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>). We have been unable to obtain further details of two unpublished studies described in <LINK REF="REF-Wallace-1994" TYPE="REFERENCE">Wallace 1994</LINK>.</P>
<P>
<B>(4) Botulinum toxin versus placebo</B>
<BR/>Three studies evaluating the use of botulinum toxin (BT) have been identified (<LINK REF="STD-Snow-1990" TYPE="STUDY">Snow 1990</LINK>; <LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK>; <LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK>). Two (<LINK REF="STD-Snow-1990" TYPE="STUDY">Snow 1990</LINK>; <LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK>) evaluated participants with thigh adductor spasticity and one (<LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK>) evaluated four participants with lower limb spasticity and one participant with upper limb spasticity. <LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK> reported a dose-ranging study, comparing 500, 1000 and 1500 units of Dysport with placebo.</P>
<P>
<B>(5) Vigabatrin versus placebo</B>
<BR/>Two unpublished cross-over trials have been identified (<LINK REF="STD-Tell-1981" TYPE="STUDY">Tell 1981</LINK>; <LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK>) using 2 to 3 g daily of vigabatrin. Only <LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK> used the Ashworth scale.</P>
<P>
<B>(6) Cannabinoids versus placebo</B>
<BR/>
<LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> reported a crossover study comparing the effects of delta9- tetrahydrocannabinol (THC), or C. sativa plant extract (containing a similar concentration of THC) with placebo. <LINK REF="STD-Wade-2003" TYPE="STUDY">Wade 2003</LINK> reported a four-way crossover study comparing THC with cannabidiol (CBD), a 1:1 mixture of THC:CBD and placebo. Both studies reported assessment of the Ashworth scale.</P>
<P>
<B>(7) Other drugs assessed using placebo-controlled trials</B>
<BR/>One crossover study evaluating prazepam (<LINK REF="STD-Levine_x0028_1_x0029_-1969" TYPE="STUDY">Levine(1) 1969</LINK>), three evaluating progabide (<LINK REF="STD-Mondrup-1984" TYPE="STUDY">Mondrup 1984</LINK>, <LINK REF="STD-Bovier-1985" TYPE="STUDY">Bovier 1985</LINK>, <LINK REF="STD-Rudick-1987" TYPE="STUDY">Rudick 1987</LINK>), one evaluating brolitene (<LINK REF="STD-Perkin-1976" TYPE="STUDY">Perkin 1976</LINK>), and one evaluating L-threonine (<LINK REF="STD-Hauser-1992" TYPE="STUDY">Hauser 1992</LINK>) have been identified. The trials of progabide and brolitene were omitted from the review as these drugs are not used therapeutically due to toxicity. Only <LINK REF="STD-Hauser-1992" TYPE="STUDY">Hauser 1992</LINK> reported use of the Ashworth scale.</P>
<P>
<B>(8) Comparison of baclofen and tizanidine</B>
<BR/>Six parallel-group studies (<LINK REF="STD-Chrzanowski-1981" TYPE="STUDY">Chrzanowski 1981</LINK>; <LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK>; <LINK REF="STD-Wuthrich-1981" TYPE="STUDY">Wuthrich 1981</LINK>; <LINK REF="STD-Stien-1987" TYPE="STUDY">Stien 1987</LINK>; <LINK REF="STD-Eyssette-1988" TYPE="STUDY">Eyssette 1988</LINK>; <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK>) and one crossover study (<LINK REF="STD-Bass-1988" TYPE="STUDY">Bass 1988</LINK>), using baclofen doses up to 90 mg and tizanidine up to 36 mg, have been reviewed. <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK> also included a group treated with tetrazepam. Only <LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK>; <LINK REF="STD-Stien-1987" TYPE="STUDY">Stien 1987</LINK> and <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK> reported use of the Ashworth scale. <LINK REF="STD-Chrzanowski-1981" TYPE="STUDY">Chrzanowski 1981</LINK> and <LINK REF="STD-Wuthrich-1981" TYPE="STUDY">Wuthrich 1981</LINK>are reported in <LINK REF="REF-Wallace-1994" TYPE="REFERENCE">Wallace 1994</LINK> as using the Ashworth scale but only the change in level of spasticity is given in the unpublished research reports. It has not been possible to obtain further details of one unpublished study (<LINK REF="STD-Wickstrom-1987" TYPE="STUDY">Wickstrom 1987</LINK>).</P>
<P>
<B>(9) Other comparative studies</B>
<BR/>
<LINK REF="STD-From-1975" TYPE="STUDY">From 1975</LINK> reported a crossover study comparing baclofen (30 to 120 mg; mean 61.2 mg) and diazepam (10 to 40 mg; mean 26.8 mg). <LINK REF="STD-Schmidt-1975" TYPE="STUDY">Schmidt 1975</LINK> reported a four-way crossover study comparing high and low doses of diazepam (8 mg and 20 mg respectively) and dantrolene (100 mg and 300 mg respectively). <LINK REF="STD-Basmajian-1984" TYPE="STUDY">Basmajian 1984</LINK> and <LINK REF="STD-Basmajian-1986" TYPE="STUDY">Basmajian 1986</LINK> described two crossover studies comparing the two benzodiazepines, ketazolam and diazepam. <LINK REF="STD-Rinne-1980" TYPE="STUDY">Rinne 1980</LINK> described three comparative trials but only one restricted to MS patients - a parallel group study comparing tizanidine (maximum 18 mg) and diazepam (22.5 mg) in 30 patients. <LINK REF="STD-Jellinger-1983" TYPE="STUDY">Jellinger 1983</LINK> reported a cross-over study comparing tizanidine with diazepam. Only <LINK REF="STD-From-1975" TYPE="STUDY">From 1975</LINK> and <LINK REF="STD-Rinne-1980" TYPE="STUDY">Rinne 1980</LINK> reported use of the Ashworth score.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>(1) Oral baclofen versus placebo</B>
<BR/>Only <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> selected participants with clinically definite MS and no trials reported the method of randomisation used. <LINK REF="STD-Sawa-1979" TYPE="STUDY">Sawa 1979</LINK> also included participants with chronic myelopathy, presumed to be MS. Most trials excluded patients with confounding conditions but <LINK REF="STD-Sachais-1977" TYPE="STUDY">Sachais 1977</LINK> included participants whose spasticity had varied in the month before the trial. All the crossover trials apart from <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> included a washout period between the arms of the trial but only <LINK REF="STD-Basmajian-1974" TYPE="STUDY">Basmajian 1974</LINK>; <LINK REF="STD-Feldman-1978" TYPE="STUDY">Feldman 1978</LINK> and <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> reported attempts to standardise the spasticity assessment. Only <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> used validated outcome measures (Ashworth score, Cybex isokinetic dynamometer (<LINK REF="REF-Bohannon-1987" TYPE="REFERENCE">Bohannon 1987</LINK>), and a questionnaire for subjective assessment of function adapted from the Minimal Record of Disability for MS (<LINK REF="REF-Haber-1985" TYPE="REFERENCE">Haber 1985</LINK>) but only results from the 30 patients who completed the study of the original 38 are reported and in summary form only. <LINK REF="STD-Feldman-1978" TYPE="STUDY">Feldman 1978</LINK> used an unvalidated spasm score and a resistance to passive movement score which is similar but not identical to the Ashworth score and the results are only tabulated for those who showed an improved score; results were only reported for the 23 out of 33 patients who completed the trial.</P>
<P>
<B>(2) Dantrolene versus placebo</B>
<BR/>No trials report the diagnostic criteria or the method of randomisation used. Only <LINK REF="STD-Sheplan-1975" TYPE="STUDY">Sheplan 1975</LINK> reports attempts to standardise assessment conditions but no validated outcome measures were used in any of the trials. <LINK REF="STD-Luisto-1982" TYPE="STUDY">Luisto 1982</LINK> included three MS participants and provided some individual patient data on request; blinding was compromised by a change in urine colour with dantrolene.</P>
<P>
<B>(3) Tizanidine versus placebo</B>
<BR/>Only <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK> reported the diagnostic criteria used and none of the three trials described the method of randomisation. All trials excluded participants with confounding conditions and other medication which could affect muscle tone was withdrawn before the trials commenced. In <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>, blinding could have been compromised by using the same doctor as assessor and prescriber during the titration phase in some centres. <LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK> made some attempt to standardise assessment conditions. In both <LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK> and <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK> significant numbers did not complete the full protocol (<LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK>: 37 participants were excluded from the analysis and 76/111 in the tizanidine group and 83/109 in the placebo group completed the study; <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>: 155 of the 187 recruited participants completed the study with little protocol violation (medication compliance &gt; 75 % and attendance at five of eight assessments - 75/94 tizanidine and 80/93 placebo) but only 70 (29 tizanidine, 41 placebo) complied with the study protocol completely). </P>
<P>In <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>, a composite "Ashworth" score was calculated combining results from assessments of ten muscle groups on each side (i.e. maximum possible score for a quadriplegic participant was 80, for a hemiplegic participant was 40 and a paraplegic participant was 32: patterns of spasticity in the two groups are not reported although the overall level of spasticity was said to be similar in each group). The group mean composite Ashworth score was calculated for each group at each visit and compared to that at baseline. Multiple statistical analyses were carried out on the many outcome measures but not corrected for multiple comparisons. <LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK> reports fewer details of the assessment of the Ashworth score but a similar method seems to have been used. <LINK REF="STD-Lapierre-1987" TYPE="STUDY">Lapierre 1987</LINK> did not use the Ashworth scale.</P>
<P>
<B>(4) Botulinum toxin (BT) versus placebo</B>
<BR/>In <LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK>, the method of randomisation is not described and the dose of BT was determined according to muscle size. The method of assessment of spasm scores is not described.</P>
<P>
<LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK> did not report the method of randomisation used. Participants with fixed hips due to established contractures, those who had suffered recent relapse and those who had recent focal or intrathecal anti-spasticity medication were excluded. The groups were well-matched for age, weight, duration of MS, degree of spasticity and EDSS score, but fewer participants in the placebo group were receiving concomitant anti-spasticity agents or analgesics. Participants continued regular physiotherapy and other concomitant anti-spasticity medication at a constant level throughout the study. A total spasticity score (product of a modified Ashworth scale and spasm frequency) was reported, which was partially validated in <LINK REF="STD-Snow-1990" TYPE="STUDY">Snow 1990</LINK> below.</P>
<P>
<LINK REF="STD-Snow-1990" TYPE="STUDY">Snow 1990</LINK> used a table of random numbers to assign the order of treatments and used rating scales which had only been partially validated (for inter-rater reliability, but not for intra-rater reliability or variability over time). The muscle tone scale used was based on but not identical with the Ashworth scale. The participants had stable spasticity and were taking no other anti-spasticity medication. Results are presented showing the change in rating scales from the onset of that arm of the trial but the absolute starting point for each arm of the trial is not reported. One of the placebo-treated participants was withdrawn from the trial after the first injection due to the development of a left hemi-paresis.</P>
<P>
<B>(5) Vigabatrin versus placebo</B>
<BR/>Neither study reported the diagnostic criteria or the method of randomisation used. Only <LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK> reported avoidance of confounding factors (other anti-spasticity medication or physiotherapy) and neither trial reported attempts to standardise assessment conditions. Both trials used unvalidated spasms scores and only <LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK> reported use of the Ashworth scale.</P>
<P>
<B>(6) Cannabinoids versus placebo</B>
<BR/>
<LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> excluded participants who had had a recent relapse, steroid or cannabinoid exposure, but did not report use of other anti-spasticity medication or physiotherapy treatment. The method of randomisation used was not reported, and blinding was probably compromised as patients (but not the assessing physicians) often guessed correctly which treatment they were taking. Outcome measures used included the mean Ashworth score, EDSS and visual analogue scores.<BR/>
<BR/>
<LINK REF="STD-Wade-2003" TYPE="STUDY">Wade 2003</LINK> included participants with intractable neurogenic symptoms (including spasticity) unresponsive to standard medications whose symptoms were stable, but no fixed criteria of baseline stability were reported. Blinding is likely to have been compromised as participants were required to use open label cannabinoid prior to commencing the study for safety reasons. Use of rescue medications was reported but concomitant physiotherapy treatment was not. Participants were permitted to titrate to the most effective dose during the first of each two week period, but there was no washout period between the treatment periods. Outcome measures used included the mean Ashworth score, mean self-rated visual analogue scales (collected over days 8 to 14 of each two week period) and two-weekly investigator numerical assessment of symptoms.<BR/>
<BR/>
<B>(7) Other drugs assessed using placebo-controlled trials</B>
<BR/>
<LINK REF="STD-Hauser-1992" TYPE="STUDY">Hauser 1992</LINK> selected participants with clinically definite MS who had been stable for at least one year. Participants were excluded if they had joint disease which would hinder assessment, required psychotropic drugs, or had received anti-spasticity treatment in the previous one month or chemotherapeutic agents in the previous six months. Randomisation was controlled by pharmacy. The movements used to assess Ashworth score were not described and results only reported as the group mean and Standard Error of the Mean (SEM). Results for other parameters were only reported qualitatively. This trial will not be assessed further.</P>
<P>
<B>(8) Comparison of baclofen and tizanidine</B>
<BR/>Only <LINK REF="STD-Bass-1988" TYPE="STUDY">Bass 1988</LINK> reported the diagnostic criteria used and only <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK> reported the method of randomisation used (minimisation). <LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK> allowed participants to continue taking regular hypnotic or psychotropic medication during the trial but other trials withdrew confounding medication. Attempts to standardise the assessment conditions were only reported in <LINK REF="STD-Bass-1988" TYPE="STUDY">Bass 1988</LINK>. <LINK REF="STD-Chrzanowski-1981" TYPE="STUDY">Chrzanowski 1981</LINK> and <LINK REF="STD-Wuthrich-1981" TYPE="STUDY">Wuthrich 1981</LINK> will not be described further as details of the methods of assessment of spasticity, spasms, clonus and function were not given, and the final drug doses used were not reported in <LINK REF="STD-Chrzanowski-1981" TYPE="STUDY">Chrzanowski 1981</LINK>. Only unvalidated measures of muscle strength were reported in the included trials.</P>
<P>
<B>(9) Other comparisons</B>
<BR/>No trials reported the diagnostic criteria or the method of randomisation. Only the ketazolam/diazepam comparative studies of <LINK REF="STD-Basmajian-1984" TYPE="STUDY">Basmajian 1984</LINK> and <LINK REF="STD-Basmajian-1986" TYPE="STUDY">Basmajian 1986</LINK> reported attempts to standardise examination conditions.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>A meta-analysis was not attempted in view of concerns about the validity of the Ashworth scale (<LINK REF="REF-Pandyan-1999" TYPE="REFERENCE">Pandyan 1999</LINK>), differences in the way the Ashworth score was assessed and inability to obtain results for the different treatment periods of crossover studies. No trials reported use of a validated spasm score. A summary of the findings of the trials is presented below.</P>
<P>
<B>(1) Oral baclofen versus placebo</B>
<BR/>
<LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK> reported significant improvement compared to placebo in angle of flexion and subjective function report for participants treated with baclofen alone or in combination with stretching exercises, but no significant added benefit from stretching exercises alone. Significantly more participants improved in Ashworth score only with baclofen combined with exercises compared with placebo.</P>
<P>
<LINK REF="STD-Feldman-1978" TYPE="STUDY">Feldman 1978</LINK> only reported the numbers of participants who improved on each treatment. Significantly better improvement was suggested in passive range of motion, painful spasms and clonus in participants taking baclofen. </P>
<P>
<B>(2) Dantrolene versus placebo</B>
<BR/>No conclusions on efficacy can be drawn as no validated outcome measures were used.</P>
<P>
<B>(3) Tizanidine versus placebo</B>
<BR/>
<LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK> reported Ashworth scores as changes from baseline in total score for all four limbs and lower limbs only (as few participants noted upper limb spasticity) and the percentage of participants showing an improvement in total Ashworth score; no significant difference was noted for the tizanidine- or placebo-treated groups in either parameter and a large placebo response was noted. Changes from baseline in total spasm and clonus scores were found not to be normally distributed, and a significantly greater effect for tizanidine was only noted after transformation of raw scores to response ratios and the performance of non-parametric statistics on the median values (post hoc analysis). No significant differences between the groups were noted in secondary end-points (including muscle power), except a better global efficacy and tolerability score (using a 11.5 cm analogue scale) with tizanidine. Large numbers of adverse events were reported (61% of placebo-treated group, 91% of tizanidine-treated group). Fourteen participants discontinued tizanidine because of side-effects (cf. six placebo): four due to dry mouth (two in placebo group), four due to somnolence, three due to dizziness (one in placebo group) and one due to drug-induced hepatitis and hallucinations.</P>
<P>In <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>, no relationship was found between the initial total muscle-tone score and dose of medication found to be optimal in the titration phase. Mean daily dose of drugs used at the end of the three-week titration phase (tizanidine 30.7 mg, placebo 35.0 mg) fell during the nine-week maintenance phase to 25.2 mg for tizanidine and 33.6 mg placebo at the end of the study. Ashworth score results were reported for all 187 randomised participants as change from baseline in group mean total Ashworth scores for all 10 muscle groups in all limbs (tizanidine 18.5 (SD 9.4) at baseline to 14.6 (SD 10.1) versus placebo 16.8 (SD 11.1) to 15.3 (SD 10.0), which was reported as being statistically significant (p = 0.004) using analysis of variance) and as percentage of participants noting an improvement of one point or more (71% with tizanidine and 50% with placebo, reported as being statistically significant (p &lt; 0.005)). The clinical significance of this finding cannot be evaluated as many muscle groups were assessed. No significant difference was noted between the tizanidine- and placebo-treated groups in EDSS, Medical Reasearch Council power grade, spasm score, pain score or eight metre walk time. Results for other secondary analyses were reported as an overall impression of change. Twenty-nine participants discontinued tizanidine prematurely (12 due to adverse effects of tiredness, drowsiness or dry mouth; 12 due to inefficacy, three due to poor co-operation, one because of an unrelated illness and one because of withdrawal effects from previous anti-spasticity medication).</P>
<P>There were no statistically significant differences between tizanidine and placebo in any of the validated assessment methods reported by <LINK REF="STD-Lapierre-1987" TYPE="STUDY">Lapierre 1987</LINK>.</P>
<P>
<B>(4) Botulinum toxin (BT) versus placebo</B>
<BR/>In <LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK> , all five participants showed a two point improvement in Ashworth score which persisted for one to three months, and a similar improvement in spasm scores was reported (results not shown) after injection of the active agent. There was no placebo effect.</P>
<P>In <LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK>, there was a statistically significant improvement greater than placebo only in the maximum distance between the knees in the 1500 unit group at the primary end-point of four weeks, but no statistically significant difference in the Ashworth scale scores. Time to requiring re-treatment was significantly greater in all BT groups than placebo. Improvement in total spasticity score was similar in all groups compared to baseline. There were more frequent reports of weakness with the botulinum toxin groups (especially at the 1500 unit dose), but otherwise reports of side-effects were similar. Some difference between the groups may have been masked by the more frequent use of concomitant anti-spasticity medication in the BT-treated groups.</P>
<P>In <LINK REF="STD-Snow-1990" TYPE="STUDY">Snow 1990</LINK>, 7/9 participants treated with BT showed an improvement in spasticity score (product of tone and spasm scores) compared with 1/9 on placebo. One participant on BT and two on placebo showed a deterioration in this score. Seven of nine participants showed an improvement in hygiene scores on BT, compared to two on placebo.</P>
<P>
<B>(5) Vigabatrin versus placebo</B>
<BR/>
<LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK> reported improvement in Ashworth score in the same number of participants with vigabatrin and placebo, but more participants with vigabatrin improved in unvalidated spasm score. <LINK REF="STD-Tell-1981" TYPE="STUDY">Tell 1981</LINK> noted no significant difference between vigabatrin and placebo in unvalidated spasticity and spasm scores.</P>
<P>
<B>(6) Cannabinoids versus placebo</B>
<BR/>
<LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> and <LINK REF="STD-Wade-2003" TYPE="STUDY">Wade 2003</LINK> both reported no significant difference in mean Ashworth score in either of the two active treatment groups compared to placebo. <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> noted a worsening in the brainstem functional systems score in the plant extract group, and a worsening in the total MS functional composite score (9 hole peg test, 25 feet timed walk, Paced Auditory Serial Addition Test) and participant' subjective global rating in the delta9- tetrahydrocannabinol (THC) treated group. <LINK REF="STD-Wade-2003" TYPE="STUDY">Wade 2003</LINK> reported a significant improvement in mean VAS scores for pain, spasms and spasticity, and numerical rating of spasticity severity and spasm frequency compared to placebo.</P>
<P>
<B>(8) Comparison of baclofen and tizanidine</B>
<BR/>
<LINK REF="STD-Bass-1988" TYPE="STUDY">Bass 1988</LINK> reported results only for the 48/66 participants who completed both treatment arms; four were excluded due to protocol violation, two due to relapse, 11 due to weakness (baclofen seven, tizanidine four), and five (on baclofen) due to nausea. Mean daily doses at the end of the treatment periods were 17.4 mg for tizanidine (range 2 to 36 mg) and 34.9 mg for baclofen (range 5 to 80 mg). No significant difference was noted in the EDSS or the unvalidated tone measures for either drug. Participants, physicians and physiotherapists generally found baclofen to be more effective than tizanidine. </P>
<P>
<LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK>, <LINK REF="STD-Stien-1987" TYPE="STUDY">Stien 1987</LINK>, <LINK REF="STD-Eyssette-1988" TYPE="STUDY">Eyssette 1988</LINK> and <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK> detected no significant differences at the doses of baclofen and tizanidine used in effects on spasticity, spasms or clonus. Only <LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK> and <LINK REF="STD-Stien-1987" TYPE="STUDY">Stien 1987</LINK> noted changes in objective muscle power (although by unvalidated or undescribed scales) with slightly more participants noting a deterioration with baclofen than tizanidine. All trials noted that slightly more participants reported weakness with baclofen than tizanidine.</P>
<P>
<B>(9) Other comparisons</B>
<BR/>
<LINK REF="STD-From-1975" TYPE="STUDY">From 1975</LINK> did not detect a significant difference between baclofen and diazepam in any of the outcome measures, except more sedation on diazepam (eleven versus five participants) and global physician preference more often for baclofen (twelve versus four comparisons). Similarly, <LINK REF="STD-Schmidt-1975" TYPE="STUDY">Schmidt 1975</LINK> (detected no difference between dantrolene and diazepam, except more sedation on diazepam (28 versus 13 participants) and overall participant preference was more often for dantrolene (22 versus 13 participants). The ketazolam/diazepam comparison of <LINK REF="STD-Basmajian-1984" TYPE="STUDY">Basmajian 1984</LINK> and <LINK REF="STD-Basmajian-1986" TYPE="STUDY">Basmajian 1986</LINK> showed no significant preference for either drug. The tizanidine/diazepam comparison of <LINK REF="STD-Rinne-1980" TYPE="STUDY">Rinne 1980</LINK> showed no significant difference in the efficacy of the two drugs but more weakness and drowsiness with diazepam; tizanidine was generally preferred. <LINK REF="STD-Jellinger-1983" TYPE="STUDY">Jellinger 1983</LINK> noted improvement in muscle tone, spasms and clonus more frequently in those taking tizanidine (assessment methods not described) and fewer participants reported tiredness or dizziness than with diazepam.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Evaluating the absolute and comparative efficacy of drug treatments for a clinical problem requires an understanding of the phenomenology of the problem and the ability to measure it. When considering the problem of spasticity it is clear that both our understanding of the problem (its pathophysiology, clinical manifestations and effect on the daily life of patients) and our ability to measure it are seriously deficient. This is reflected in the wide variety of approaches taken to assess spasticity in the trials we have reviewed and the inconclusive objective results of the vast majority of the trials. </P>
<P>Methodological quality of trials (especially in the control for confounding factors and the choice of assessment tools which are validated for inter- and intra-rater reliability) is clearly improving, if one compares the baclofen trials of the 1970s with the tizanidine trials of the 1990s. However, difficulty remains in even demonstrating the efficacy of active drug against placebo (quite apart from the statistical difficulty in assessing non-parametric scales and the complexity of multiple sclerosis compared with monophasic conditions such as stroke and spinal cord injury). There remains a gap between published evidence and the daily experience of those who manage spasticity. Better assessment tools are needed to confirm the clinical impression that the widely used anti-spasticity drugs (baclofen, dantrolene, tizanidine) are more effective that placebo. Only then can comparative studies be expected to evaluate the comparative efficacy of different agents.</P>
<P>The validity of the Ashworth scale, the only widely used assessment tool for spasticity, has been seriously questioned (<LINK REF="REF-Pandyan-1999" TYPE="REFERENCE">Pandyan 1999</LINK>) and we are not aware of any validated method of assessing spasm scores. Sixteen of the studies we have summarised reported an "Ashworth scale" (<LINK REF="STD-From-1975" TYPE="STUDY">From 1975</LINK>; <LINK REF="STD-Rinne-1980" TYPE="STUDY">Rinne 1980</LINK>; <LINK REF="STD-Chrzanowski-1981" TYPE="STUDY">Chrzanowski 1981</LINK>; <LINK REF="STD-Smolenski-1981" TYPE="STUDY">Smolenski 1981</LINK>; <LINK REF="STD-Wuthrich-1981" TYPE="STUDY">Wuthrich 1981</LINK>; <LINK REF="STD-Joder_x002d_Ohlenbusch-_x0027_84" TYPE="STUDY">Joder-Ohlenbusch '84</LINK>;<LINK REF="STD-Stien-1987" TYPE="STUDY">Stien 1987</LINK>; <LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK>; <LINK REF="STD-Hauser-1992" TYPE="STUDY">Hauser 1992</LINK>; <LINK REF="STD-Smith-1994" TYPE="STUDY">Smith 1994</LINK>; <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>; <LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK>; <LINK REF="STD-Pellkofer-1989" TYPE="STUDY">Pellkofer 1989</LINK>; <LINK REF="STD-Hyman-2000" TYPE="STUDY">Hyman 2000</LINK>; <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK>; <LINK REF="STD-Wade-2003" TYPE="STUDY">Wade 2003</LINK>) but used different methods to assess and score the Ashworth scale results, so a meta-analysis was not attempted. Only three (<LINK REF="STD-Brar-1991" TYPE="STUDY">Brar 1991</LINK>; <LINK REF="STD-UKTTG-1994" TYPE="STUDY">UKTTG 1994</LINK>; <LINK REF="STD-Grazko-1995" TYPE="STUDY">Grazko 1995</LINK>) of the placebo-controlled (absolute efficacy) trials which reported Ashworth scale results showed a statistically significant superior effect of active drug over placebo. None of the comparative studies were able to show a statistical difference between the trial drugs.</P>
<P>The concept of weakness reported by patients with spasticity is poorly characterised. A patient reporting weakness may be referring to a reduction in static limb muscle power (although scant evidence for this was present in these trials), reduction in power of postural trunk muscles, fatigue or some other central effect. Evidence for differences between drugs was limited to unvalidated limb power scores and patient side-effect reports (cf. baclofen/tizanidine comparative trials). Also, the finding that "more patients report weakness with drug A than drug B" does not necessarily imply that patients on drug A will notice an increase in muscle power if they are changed to drug B.</P>
<P>The decision to treat a patient with anti-spasticity medication is made for different reasons in different patients, especially in a disease with such varied clinical manifestations as multiple sclerosis: the immobile patient is treated for symptomatic relief (pain and spasms) and in order to make nursing care and seating easier, whereas the ambulant patient is treated with the additional aim of improving or preserving mobility. Different manifestations of the upper motor neurone syndrome are treated in different cases (e.g spasms, associated reactions) and it cannot be assumed that the effect on resistance to passive stretch can be taken as a surrogate marker for all these: the diagnostic examination of the neurologist is not always an adequate predictor of the functional examination of the physiotherapist or the daily experience of the patient. The currently available evidence does not help to answer the question of which agents are best for treating different spasticity scenarios. The development of more appropriate outcome measures will require better phenomenological and neurophysiological characterisation of these spasticity scenarios, probably by a multidisciplinary neuro-rehabilitation team.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This systematic review has identified a large number of studies which have attempted to assess the absolute and comparative efficacy of various anti-spasticity agents in multiple sclerosis. The variability of spasticity and the lack of a sensitive, reliable, functionally- and symptomatically-relevant assessment tool for spasticity have contributed to the inconclusive results of placebo-controlled trials attempting to document the efficacy of anti-spasticity agents which are in widespread use. Comparative studies have been similarly inconclusive. No firm recommendations to change practice can be made from this systematic review, and in particular there is no good evidence to prefer newer over older agents.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is an urgent need for assessment tools for spasticity and other components of the upper motor neurone syndrome which are sensitive and well-validated. Such measures must correspond to the daily patient experience of spasticity and be used in comparative studies of older and newer drugs before firm recommendations to change to newer agents can be made. Studies of anti-spasticity medication should not be carried out without similar studies of the non-drug management of spasticity. The recognition that there are a variety of spasticity scenarios and reasons for wanting to treat spasticity may assist the design of trials which are likely to be able to answer the questions posed by the day-to-day management of multiple sclerosis patients troubled by spasticity.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We received invaluable help in obtaining references from the Librarians at the Postgraduate Library, University Hospital Aintree, the Librarians at the British Medical Association Library, London, and from Dr Lee Durham (Macon, Georgia, USA). Patrick Weiderseiner and Dr Ian Scott provided translations of some of the foreign language articles.</P>
<P>We thank the following experts for commenting on our protocol and assisting us in identifying relevant trials: Prof R Hohlfield &amp; Dr F Then Bergh (Munich, Germany), Dr M Kita &amp; Dr D E Goodkin (San Francisco, USA), Prof D Wade (Oxford, UK), Prof M Barnes (Newcastle, UK), Prof O Hommes (Nijmegen, Netherlands), Prof A Thompson (London, UK), Prof B Arnason (Chicago, USA), Dr R T Schapiro (Minneapolis, USA).</P>
<P>We thank the following pharmaceutical companies for assisting us in the identification of published and unpublished trials, for providing copies of some references and for providing details of unpublished trials as noted in the review: Novartis, Proctor and Gamble, Athena, Elan Pharma, Parke-Davis Medical, Aventis Pharma, Allergan, Ipsen.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All three reviewers contributed to the design of the protocol, assessment of studies, extraction of data and writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-22 10:01:25 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDIES MODIFIED="2008-08-22 09:59:59 +0200" MODIFIED_BY="Deirdre Beecher">
<INCLUDED_STUDIES MODIFIED="2008-07-02 11:44:07 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1974" NAME="Basmajian 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Basmajian J, Yucel V. Effects of GABA-derivative (BA-34647) on spasticity. American Journal of Physical Medicine 1974;53(5):223-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Yucel V</AU>
<TI>Effects of GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study &amp; rehabilitation</TI>
<SO>American Journal of Physical Medicine</SO>
<YR>1974</YR>
<VL>53</VL>
<NO>5</NO>
<PG>223-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1975" MODIFIED="2008-07-02 11:44:07 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Basmajian 1975" YEAR="1975">
<REFERENCE MODIFIED="2008-07-02 11:44:07 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV</AU>
<TI>Lioresal (baclofen) treatment of spasticity in multiple sclerosis</TI>
<SO>American Journal of Physical Medicine</SO>
<YR>1975</YR>
<VL>54</VL>
<NO>4</NO>
<PG>175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1984" NAME="Basmajian 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Basmajian JV, et al. Ketazolam treatment for spasticity: double-blind study of a new drug. Archives of Physical Medicine &amp;amp; Rehabilitation 1984;65(11):698-701.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Shankardass K, Russell D</AU>
<TI>Ketazolam treatment for spasticity: double-blind study of a new drug</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1984</YR>
<VL>65</VL>
<NO>11</NO>
<PG>698-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1986" NAME="Basmajian 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Basmajian, J.V., K. Shankardass, and D. Russell. Ketazolam once daily for spasticity: double-blind cross-over study. Archives of Physical Medicine &amp;amp; Rehabilitation, 1986. 67(8): p. 556-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Shankardass K, Russell D</AU>
<TI>Ketazolam once daily for spasticity: double-blind cross-over study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>8</NO>
<PG>556-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bass-1988" NAME="Bass 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Bass, B., et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 1988. 15(1): p. 15-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bass B, Weinshenker B, Rice GP, Neseworthy JH, Cameron MG, Hader W, et al</AU>
<TI>Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1988</YR>
<VL>15</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bovier-1985" NAME="Bovier 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Bovier, P., C. Cambier, and P. Morselli. Etude en double-aveugle du progabide dans le spasticite. Therapie, 1985. 40: p. 181-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bovier P, Cambier J, Morselli PL</AU>
<TI>Double-blind study of progabide in spasticity</TI>
<TO>Etude en double-aveugle du progabide dans le spasticite</TO>
<SO>Therapie</SO>
<YR>1985</YR>
<VL>40</VL>
<NO>3</NO>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brar-1991" NAME="Brar 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Brar, S., et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Archives of Physical Medicine &amp;amp; Rehabilitation, 1991. 72: p. 186-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brar Sp, Smith MB, Nelson LM, Franklin GM, Cobble ND</AU>
<TI>Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1991</YR>
<VL>72</VL>
<NO>3</NO>
<PG>186-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Chrzanowski-1981" NAME="Chrzanowski 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Chrzanowski, K. A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study no. 26), . 1981, Unpublished Sandoz Research Report.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Chrzanowski K</AU>
<TI>A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study no. 26)</TI>
<SO>Unpublished Sandoz Research Report</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Chrzanowski, C. A new muscle relaxant, DS 103-282, versus baclofen in the treatment of chronic spasticity. in 8th International Congress of Physical Medicine and Rehabilitation. 1980. Stockholm, Sweden: Print Minab, Sweden.&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Chrzanowski, C</AU>
<TI>A new muscle relaxant, DS 103-282, versus baclofen in the treatment of chronic spasticity</TI>
<SO>8th International Congress of Physical Medicine &amp; Rehabilitation</SO>
<YR>1980</YR>
<PG>45</PG>
<PB>Print Minab</PB>
<CY>Sweden</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eyssette-1988" NAME="Eyssette 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Eyssette, M., et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current Medical Research &amp;amp; Opinion, 1988. 10(10): p. 699-708.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D</AU>
<TI>Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1988</YR>
<VL>10</VL>
<NO>10</NO>
<PG>699-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-1978" NAME="Feldman 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Feldman, R.G., et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology, 1978. 28(11): p. 1094-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM</AU>
<TI>Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1094-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-From-1975" NAME="From 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;From, A. and A. Heltberg. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurologica Scandinavica, 1975. 51(2): p. 158-66.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>From A, Heltberg A</AU>
<TI>A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1975</YR>
<VL>51</VL>
<NO>2</NO>
<PG>158-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelenberg-1973" NAME="Gelenberg 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Gelenberg, A.J. and D.C. Poskanzer. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology, 1973. 23(12): p. 1313-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gelenberg AJ, Poskanzer DC</AU>
<TI>The effect of dantrolene sodium on spasticity in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1973</YR>
<VL>23</VL>
<NO>12</NO>
<PG>1313-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grazko-1995" NAME="Grazko 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Grazko, M., K. Polo, and B. Jabbari. Botulinum toxin A for spasticity. muscle spasms and rigidity. Neurology, 1995. 45: p. 712-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grazko MA, Polo KB, Jabbari B</AU>
<TI>Botulinum toxin A for spasticity, muscle spasms, and rigidity</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>4</NO>
<PG>712-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauser-1992" NAME="Hauser 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Hauser, S.L., et al. An antispasticity effect of threonine in multiple sclerosis. Archives of Neurology, 1992. 49(9): p. 923-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hauser SL, Doolittle TH, Lopez-Bresnahan M, Shahani B, Schoenfeld D, Shin VE, et al</AU>
<TI>An antispasticity effect of threonine in multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>9</NO>
<PG>923-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hyman-2000" NAME="Hyman 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreeczy-Kleedorfer B et al</AU>
<TI>Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2000</YR>
<VL>68</VL>
<NO>6</NO>
<PG>707-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jellinger-1983" NAME="Jellinger 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Jellinger, K. A controlled, double-blind, clinical, therapeutic, comparative study with two parallel groups (tizanidine and diazepam) in ambulant/hospitalized patients with multiple sclerosis. Unpublished Sandoz Research Report, 1983.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Jellinger K</AU>
<TI>A controlled, double-blind, clinical, therapeutic, comparative study with two parallel groups (tizanidine and diazepam) in ambulant/hospitalized patients with multiple sclerosis</TI>
<SO>Unpublished Sandoz Research Report</SO>
<YR>1983</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Jellinger, K. Zur Behandlung der Spastizitat  bei multipler Sklerose-Ergebnisse einer Doppelblindstudies mit Tizanidin und Diazepham, in Die klinische Wertung der Spastizitat, B. Conrad, R. Benecke, and H. Bauer, Editors. 1984, Schattauer: Stuttgart. p. 171-185.&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Jellinger K</AU>
<TO>Zur Behandlung der Spastizitat bei multipler Sklerose-Ergebnisse einer Doppelblindstudies mit Tizanidin und Diazepam</TO>
<SO>Die klinische Wertung der Spastizitat</SO>
<YR>1984</YR>
<PG>171-185</PG>
<ED>Conrad B, Benecke R, Bauer H</ED>
<PB>Schattauer</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Joder_x002d_Ohlenbusch-_x0027_84" NAME="Joder-Ohlenbusch '84" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Joder-Ohlenbusch AM, Schechter PJ. Double-blind, placebo-controlled, crossover study of -vinyl GABA treatment in spasticity. Unpublished Research Report, 1984.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Joder-Ohlenbusch AM, Schechter PJ</AU>
<TI>Double-blind, placebo-controlled, crossover study of -vinyl GABA treatment in spasticity</TI>
<SO>Unpublished Research Report</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killestein-2002" MODIFIED="2008-07-02 11:42:50 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Killestein 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-07-02 11:42:50 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, van Loenen AC, Staats PGM et al</AU>
<TI>Safety, tolerability, and efficacy of orally administered cannabinoids in MS</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>9</NO>
<PG>1404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1987" NAME="Lapierre 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD, Bouchard S, Tansey C, Gedron D, Barkas WJ, Francis CB</AU>
<TI>Treatment of spasticity with tizanidine in multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>3 Suppl</NO>
<PG>513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine_x0028_1_x0029_-1969" NAME="Levine(1) 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Levine, I., et al. Prazepam in the treatment of spasticity. A quantitative double-blind evaluation. Neurology, 1969. 19: p. 510-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine I, Jossmann PB, Friend DG, DeAngelis V</AU>
<TI>Prazepam in the treatment of spasticity. A quantitative double-blind evaluation</TI>
<SO>Neurology</SO>
<YR>1969</YR>
<VL>19</VL>
<NO>5</NO>
<PG>510-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Luisto-1982" NAME="Luisto 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Luisto, M., et al. Dantrolene sodium in chronic spasticity of varying etiology. Acta Neurologica Scandinavica, 1982. 65: p. 355-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luisto M, Moller K, Nuutila A, Palo J</AU>
<TI>Dantrolene sodium in chronic spasticity of varying etiology. A double-blind study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1982</YR>
<VL>65</VL>
<NO>4</NO>
<PG>355-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pellkofer-1989" NAME="Pellkofer 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Pellkofer, M. and M. Paulig. [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. Medizinische Klinik, 1989. 84(1): p. 5-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pellkofer M, Paulig M</AU>
<TI>Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities</TI>
<SO>Medizinische Klinik</SO>
<YR>1989</YR>
<VL>84</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinne-1980" NAME="Rinne 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Rinne, U. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Current Therapeutic Research, 1980. 28: p. 827-36.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rinne U</AU>
<TI>Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy</TI>
<SO>Current Therapeutic Research</SO>
<YR>1980</YR>
<VL>28</VL>
<PG>827-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachais-1977" NAME="Sachais 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Sachais, B., J. Logue, and M. Carey. Baclofen, a new antispastic drug. Archives of Neurology, 1977. 34(7): p. 422-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sachais BA, Logue JN, Carey MS</AU>
<TI>Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>7</NO>
<PG>422-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawa-1979" NAME="Sawa 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Sawa, G.M. and D.W. Paty. The use of baclofen in treatment of spasticity in multiple sclerosis. Canadian Journal of Neurological Sciences, 1979. 6(3): p. 351-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sawa GM, Paty DW</AU>
<TI>The use of baclofen in treatment of spasticity in multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1979</YR>
<VL>6</VL>
<NO>3</NO>
<PG>351-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1975" NAME="Schmidt 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Schmidt, R., R. Lee, and R. Spehlmann. Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam. Trans  Am Neurol Assoc, 1975. 100: p. 235-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt RT Lee RH, Spehlmann R</AU>
<TI>Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam</TI>
<SO>Transactions of the American Neurology Association</SO>
<YR>1975</YR>
<VL>100</VL>
<PG>235-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Schmidt, R.T., R.H. Lee, and R. Spehlmann. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1976. 39(4): p. 350-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt RT, Lee RH, Spehlmann R</AU>
<TI>Comparison of dantrolene sodium and diazepam in the treatment of spasticity</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1976</YR>
<VL>39</VL>
<NO>4</NO>
<PG>350-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheplan-1975" NAME="Sheplan 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Sheplan, L. and C. Ishmael. Spasmolytic properties of dantrolene sodium. Clinical evaluation. Military Medicine, 1975. 140: p. 26.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sheplan L, Ishmael C</AU>
<TI>Spasmolytic properties of dantrolene sodium: Clinical evaluation</TI>
<SO>Military Medicine</SO>
<YR>1975</YR>
<VL>140</VL>
<NO>1</NO>
<PG>26-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1994" NAME="Smith 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Smith, C., et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology, 1994. 44(11 Suppl 9): p. S34-42.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith C, Birnbaum G, Carter Jl, Greenstein J, Lublin FD</AU>
<TI>Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44 Suppl 9</VL>
<NO>11</NO>
<PG>S34-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smolenski-1981" NAME="Smolenski 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Smolenski, C., S. Muff, and S. Smolenski-Kautz. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Current Medical Research &amp;amp; Opinion, 1981. 7(6): p. 374-83.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smolenski C, Muff S, Smolenski-Kautz S</AU>
<TI>A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>6</NO>
<PG>374-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snow-1990" NAME="Snow 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Snow, B.J., et al. Treatment of spasticity with botulinum toxin: a double-blind study. Annals of Neurology, 1990. 28(4): p. 512-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB-</AU>
<TI>Treatment of spasticity with botulinum toxin: a double-blind study</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>28</VL>
<NO>4</NO>
<PG>512-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stien-1987" NAME="Stien 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Stien, R., et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurologica Scandinavica, 1987. 75(3): p. 190-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stien R, Nordal HJ, Oftedal SI, Slettebo M</AU>
<TI>The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1987</YR>
<VL>75</VL>
<NO>3</NO>
<PG>190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Tell-1981" NAME="Tell 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Tell, G (1981). Double-blind, placebo-controlled crossover study of multiple oral doses of RMI 71,754 (Vigabatrin) in ten hospitalised patients with muscle spasticity&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Tell G</AU>
<TI>Double-blind, placebo-controlled crossover study of multiple oral doses of RMI 71,754 (Vigabatrin) in ten hospitalised patients with muscle spasticity</TI>
<SO>Unpublished Research Report</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tolosa-1975" NAME="Tolosa 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Tolosa, E., R. Soll, and R. Loewenson. Treatment of spasticity in multiple sclerosis with dantrolene. Journal of the American Medical Association, 1975. 233(10): p. 1046.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tolosa ES, Soll RW, Loewenson RB</AU>
<TI>Treatment of spasticity in multiple sclerosis with dantrolene</TI>
<SO>Journal of American Medical Association</SO>
<YR>1975</YR>
<VL>233</VL>
<NO>10</NO>
<PG>1046</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKTTG-1994" NAME="UKTTG 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;UKTTG. A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. The United Kingdom Tizanidine Trial Group. Neurology, 1994. 44(44 (Suppl 9)): p. S70-S78.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The United Kingdom Tizanidine Trial Group</AU>
<TI>A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44 Suppl 9</VL>
<NO>11</NO>
<PG>S70-S78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wade-2003" NAME="Wade 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wade DT, Robson P, House H, Makela P, Aram J</AU>
<TI>A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wuthrich-1981" NAME="Wuthrich 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Wuthrich, R. A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study No 31). 1981, Unpublished Sandoz Research Report.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Wuthrich, R</AU>
<TI>A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study No 31)</TI>
<SO>Unpublished Sandoz Research Report</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-22 09:59:59 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Abel-1994" NAME="Abel 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Abel, N.A. and R.A. Smith. Intrathecal baclofen for treatment of intractable spinal spasticity. Archives of Physical Medicine &amp;amp; Rehabilitation, 1994. 75(1): p. 54-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abel NA, Smith RA</AU>
<TI>Intrathecal baclofen for treatment of intractable spinal spasticity</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1994</YR>
<VL>75</VL>
<NO>1</NO>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1973" NAME="Anonymous 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Anonymous. A phenothiazine in spasticity. Practitioner, 1973. 210(257): p. 429-31.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>A phenothiazine in spasticity</TI>
<SO>Practitioner</SO>
<YR>1973</YR>
<VL>210</VL>
<NO>257</NO>
<PG>429-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1974" NAME="Anonymous 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Anonymous. A comparative trial of dimethothiazine in spastic conditions. Practitioner, 1974. 213(1273): p. 101-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>A comparative trial of dimethothiazine in spastic conditions</TI>
<SO>Practitioner</SO>
<YR>1974</YR>
<VL>213</VL>
<NO>1273</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azouvi-1996" NAME="Azouvi 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Azouvi, P et al. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Archives of Physical Medicine &amp;amp; Rehabilitation, 1996. 77(1): p. 35-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B</AU>
<TI>Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1996</YR>
<VL>71</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barat-1974" NAME="Barat 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Barat, M., et al. Treatment of spasticity with Lioresal: clinical trial involving 47 cases. Bordeaux Med, 1974. 7: p. 1435-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barat M, et al</AU>
<TI>Treatment of spasticity with Lioresal: clinical trial involving 47 cases</TI>
<SO>Bordeaux Medical</SO>
<YR>1974</YR>
<VL>7</VL>
<PG>1435-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbeau-1982" NAME="Barbeau 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Barbeau, H., C.L. Richards, and P.J. Bedard. Action of cyproheptadine in spastic paraparetic patients. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1982. 45(10): p. 923-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barbeau H, Richards CL, Bedard PJ</AU>
<TI>Action of cyproheptadine in spastic paraparetic patients</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1982</YR>
<VL>45</VL>
<NO>10</NO>
<PG>923-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basmajian-1973" NAME="Basmajian 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Basmajian, J. and G. Super. Dantrolene sodium in the treatment of spasticity. Archives of Physical Medicine &amp;amp; Rehabilitation, 1973. 54: p. 60-64.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basmajian JV, Super GA</AU>
<TI>Dantrolene sodium in the treatment of spasticity</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1973</YR>
<VL>54</VL>
<NO>2</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baykuschev-1968" NAME="Baykuschev 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Baykuschev, S. [The effect of chlorpromazine on inhibitory processes in the spinal cord of patients with spastic paralyses]. Deutsche Zeitschrift fur Nervenheilkunde, 1968. 194(4): p. 318-27.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baykuschev S</AU>
<TI>[The effect of chlorpromazine on inhibitory processes in the spinal cord of patients with spastic paralyses] [German]</TI>
<SO>Deutsche Zeitschrift fur Nervenheilkunde</SO>
<YR>1968</YR>
<VL>194</VL>
<NO>4</NO>
<PG>318-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1995" NAME="Becker 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Becker, W.J., et al. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Canadian Journal of Neurological Sciences, 1995. 22(3): p. 208-17.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, De Forge DA</AU>
<TI>Long-term intrathecal baclofen therapy in patients with intractable spasticity</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>3</NO>
<PG>208-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behan-1982" NAME="Behan 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Behan, P. An evaluation of low dose dantrolene sodium (Dantrium) therapy in the treatment of ambulatory patients with spasticity. Clinical Trials Journal, 1982. 19: p. 1-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Behan P</AU>
<TI>An evaluation of low dose dantrolene sodium (Dantrium) therapy in the treatment of ambulatory patients with spasticity</TI>
<SO>Clinical Trials Journal</SO>
<YR>1982</YR>
<VL>19</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergamini-1966" NAME="Bergamini 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Bergamini, L., A. Riccio, and B. Bergamasco. Un farmaco ad azione antispastica della musculatura striata: Sperimentazione clinica di un derivativo del GABA. Minerva Med, 1966. 57: p. 2723-29.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bergamini L, Riccio A, Bergamasco B</AU>
<TI>A drug with antispastic action on striated muscle. Clinical Trial of derivative of GAVA</TI>
<TO>Un farmaco ad azione antispastica della musculatura striata. Sperimentazione clinica di un derivativo del GABA</TO>
<SO>Minerva Medica</SO>
<YR>1966</YR>
<VL>57</VL>
<NO>65</NO>
<PG>2723-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchi-1999" NAME="Bianchi 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Bianchi L, Monaldi F, Paolucci S, Iani C, Lacquaniti F (1999). Quantitative analysis of the pendulum test: Application to multiple sclerosis patients treated with botulinum toxin. Functional Neurology 14: 2; 79-92.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi L, Monaldi F, Paolucci S, Iani C, Lacquaniti F</AU>
<TI>Quantitative analysis of the pendulum test: application to multiple sclerosis patients treated with botulinum toxin</TI>
<SO>Functional Neurology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>79-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkmayer-1967" NAME="Birkmayer 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Birkmayer, W., W. Danielczynk, and G. Weiler. An objective assessment of the monolytic effects of an aminobuutyric acid derivative (CIBA 34647-Ba). Wiener Medizinische Wochenschrift, 1967. 117: p. 7-14.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Birkmayer W, Danielczynk W, Weiler G</AU>
<TI>[An objective assessment of the monolytic effects of an aminobuutyric acid derivative (CIBA 34647-Ba)] [German]</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1967</YR>
<VL>117</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bittencourt-1988" NAME="Bittencourt 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Bittencourt, P. Oxcarbazepine and spasticity: further observations. Arq Neuro-Psiquiatr (Sao Paolo), 1988. 46(4): p. 382-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bittencourt PR</AU>
<TI>Oxcarbazepine and spasticity: further observations</TI>
<SO>Arquivos de Neuro-Psiquiatria</SO>
<YR>1988</YR>
<VL>46</VL>
<NO>4</NO>
<PG>382-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broggi-1993" NAME="Broggi 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Broggi, G., et al. The treatment of spasticity by intrathecal administration of baclofen: a preliminary personal experience. Journal of Neurosurgical Sciences, 1993. 37(4): p. 203-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Broggi G, Servello D, Brocks S, Dones I</AU>
<TI>The treatment of spasticity by intrathecal administration of baclofen: a preliminary personal experience</TI>
<SO>Journal of Neurosurgical Sciences</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>4</NO>
<PG>203-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broseta-1989" NAME="Broseta 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Broseta, J., et al. Use of intrathecal baclofen administered by programmable infusion pumps in resistant spasticity. Acta Neurochirurgica, 1989. Supplement 46: p. 39-45.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Broseta J, Morales F, Garcia-March G, Sanchez-Ledesma MJ, Anaya J, Gonzales-Darder J, et al</AU>
<TI>Use of intrathecal baclofen administered by programmable infusion pumps in resistant spasticity</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1989</YR>
<VL>46 Suppl</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burke-1971" NAME="Burke 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Burke, D., C. Andrews, and L. Knowles. The action of a GABA derivative in human spasticity. Journal of Neurological Sciences, 1971. 14: p. 199-208.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burke D, Andrews CJ, Knowles L</AU>
<TI>The action of a GABA derivative in human spasticity</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1971</YR>
<VL>14</VL>
<NO>2</NO>
<PG>199-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cartlidge-1974" NAME="Cartlidge 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Cartlidge, N.E., P. Hudgson, and D. Weightman. A comparison of baclofen and diazepam in the treatment of spasticity. Journal of the Neurological Sciences, 1974. 23(1): p. 17-24.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cartlidge NE, Hudgson P, Weightman D</AU>
<TI>A comparison of baclofen and diazepam in the treatment of spasticity</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1974</YR>
<VL>23</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castaigne-1973" NAME="Castaigne 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Castaigne, P., et al. Study of the effect of Lioresal on spasticity. Nouv Press Med, 1973. 2: p. 2341-2.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Castaigne JP, Laplane D, Pierrot-Deseilligny E, Bussel B, Macquart-Moulin J</AU>
<TI>[Trial of Lioresal in the treatment of spasticity] [French]</TI>
<SO>Nouvelle Presse Medicale</SO>
<YR>1973</YR>
<VL>2</VL>
<NO>35</NO>
<PG>2341-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cendrowski_x0028_1_x0029_-1977" NAME="Cendrowski(1) 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Cendrowski, W. and W. Sobczyk. Clonazepam, baclofen and placebo in the treatment of spasticity. European Neurology, 1977. 16(1-6): p. 257-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cendrowski W, Sobczyk W</AU>
<TI>Clonazepam, baclofen and placebo in the treatment of spasticity</TI>
<SO>European Neurology</SO>
<YR>1977</YR>
<VL>16</VL>
<NO>1-6</NO>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cendrowski_x0028_2_x0029_-1977" NAME="Cendrowski(2) 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Cendrowski, W. Dantrium in treatment of increased muscle tonus - in patients with multiple sclerosis. Neur Neurochir Pol, 1977. 11: p. 117-21.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cendrowski W</AU>
<TI>Dantrium in the treatment of increased muscle tonus in patients with multiple sclerosis</TI>
<SO>Neurologia I Neurochirurgia Polska</SO>
<YR>1977</YR>
<VL>11</VL>
<NO>1</NO>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chantraine-1980" NAME="Chantraine 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Chantraine, A. and C. van Ouwenaller. [Treatment of spasticity in neurological disease by dantrolen-sodium (author's transl)]. Nervenarzt, 1980. 51(1): p. 50-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chantraine A, van Ouwenaller C</AU>
<TI>[Treatment of spasticity in neurological disease by dantrolen-sodium] [German]</TI>
<SO>Nervenarzt</SO>
<YR>1980</YR>
<VL>51</VL>
<NO>1</NO>
<PG>50-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chipman-1974" NAME="Chipman 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Chipman, M., S. Kaul, and M. Lambie. Efficacy of dantrolene sodium in the treatment of spasticity. Diseases of the Nervous System, 1974. 35: p. 427ff.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chipman M, Kaul S, Lambie M</AU>
<TI>Efficacy of dantrolene sodium in the treatment of spasticity</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<PG>427ff</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chyatte-1971" NAME="Chyatte 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Chayatte, S. and J. Birdsong. The use of dantrolene sodium in disorders of the central nervous system. Southern Medical Journal, 1971. 64(7): p. 830-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chayatte SB, Birdsong JH</AU>
<TI>The use of dantrolene sodium in disorders of the central nervous system</TI>
<SO>Southern Medical Journal</SO>
<YR>1971</YR>
<VL>64</VL>
<NO>7</NO>
<PG>830-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coffey-1993" NAME="Coffey 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Coffey, R., et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. Journal of Neurosurgery, 1993. 78(2): p. 226-32.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coffey RJ, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al</AU>
<TI>Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1993</YR>
<VL>78</VL>
<NO>2</NO>
<PG>226-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohan-1980" NAME="Cohan 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Cohan, S., et al. Phenytoin and chlorpromazine in the treatment of spasticity. Archives of Neurology, 1980. 37: p. 360-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohan SL, Raines A, Panagakos J, Armitage P</AU>
<TI>Phenytoin and chlorpromazine in the treatment of spasticity</TI>
<SO>Archives of Neurology</SO>
<YR>1980</YR>
<VL>37</VL>
<NO>6</NO>
<PG>360-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corston--1981" NAME="Corston  1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Corston, R., F. Johnson, and R. Godwin-Austen. The assessment of drug treatment of spastic gait. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1981. 44: p. 1035-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Corston RN, Johnson F, Godwin-Austen RB</AU>
<TI>The assessment of drug treatment of spastic gait</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1981</YR>
<VL>44</VL>
<NO>11</NO>
<PG>1035-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cumming-1972" NAME="Cumming 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Cumming, R. Multiple sclerosis in the Shetlands, with an evaluation of Lioresal. Postgraduate Medical Journal, 1972. 48:Suppl(5): p. 34-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cumming R</AU>
<TI>Multiple sclerosis in the Shetlands, with an evaluation of Lioresal</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1972</YR>
<VL>48</VL>
<NO>Suppl 5</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cutter-2000" NAME="Cutter 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Duration less than 7 days&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cutter NC, Scott DD, Johnson JC, Whiteneck G</AU>
<TI>Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2000</YR>
<VL>81</VL>
<NO>2</NO>
<PG>164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dressnandt-1996" NAME="Dressnandt 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Dressnandt, J. and B. Conrad. Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1996. 60(2): p. 168-73.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dressnandt J, Conrad B</AU>
<TI>Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<NO>2</NO>
<PG>168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duncan-1976" NAME="Duncan 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Duncan, G., B. Shahani, and R. Young. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology, 1976. 26(5): p. 441-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Duncan GW, Shahani BT, Young RR</AU>
<TI>An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study</TI>
<SO>Neurology</SO>
<YR>1976</YR>
<VL>26</VL>
<NO>5</NO>
<PG>441-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunevsky-1998" NAME="Dunevsky 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dunevsky A, Perel AB</AU>
<TI>Gabapentin for relief of spasticity associated with multiple sclerosis</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>5</NO>
<PG>451-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emre-1994" NAME="Emre 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Emre, M., et al. Correlations between dose, plasma concentrations and antispastic action of tizanidine (Sirdalud). Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1994. 57(11): p. 1355-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emre M, Leslie GC, Muir C, Part NJ, Pokorney R, Roberts RC</AU>
<TI>Correlations between dose, plasma concentrations and antispastic action of tizanidine (Sirdalud)</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>11</NO>
<PG>1355-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finnimore-1995" NAME="Finnimore 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Finnimore, A., et al. The effects of the GABA agonist, baclofen, on sleep and breathing. European Respiratory Journal, 1995. 8: p. 230-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Finnimore AJ, Roebuck M, Sajkov D, McEvoy RD</AU>
<TI>The effects of the GABA agonist, baclofen, on sleep and breathing</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>2</NO>
<PG>230-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fra-1971" NAME="Fra 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Fra, L., et al. [Study of the H reflex in spastic subjects treated with a GABA derivative (Ciba 34647-BA)]. Rivista di Neurologia, 1971. 41(3): p. 152-60.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fra L, Bergamini L, Brignolio F, Delsedime M</AU>
<TI>[Study of the H reflex in spastic subjects treated with a GABA derivative (Ciba 34647-BA)] [Italian]</TI>
<SO>Rivista di Neurologia</SO>
<YR>1971</YR>
<VL>41</VL>
<NO>3</NO>
<PG>152-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gambi-1983" NAME="Gambi 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Gambi, D., et al. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind crossover study in comparison with placebo. Current Therapeutic Research, 1983. 33: p. 835-40.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gambi D, Rossini PM, Calenda G</AU>
<TI>Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind crossover study in comparison with placebo</TI>
<SO>Current Therapeutic Research</SO>
<YR>1983</YR>
<VL>33</VL>
<PG>835-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerstenbrand-1979" NAME="Gerstenbrand 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Gerstenbrand, F., et al. [Long-term treatment with an imidazoline derivative (DS 103--282)]. Nervenarzt, 1979. 50(12): p. 806-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gerstenbrand F, Lorincz A, Ludin Hp, Ringwald E</AU>
<TI>[Long-term treatment with an imidazoline derivative (DS 103--282)] [German]</TI>
<SO>Nervenarzt</SO>
<YR>1979</YR>
<VL>50</VL>
<NO>12</NO>
<PG>806-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbins-1982" NAME="Gibbins 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Gibbins, F.J., A.M. Lewis, D.K. Kesar. Effectiveness and safety of dantrolene sodium in comparison with baclofen in spasticity from multiple sclerosis. Cross-over study. In: Dantrolene sodium: New therapeutic approach to clinical problems of spasticity, Proceedings of the International Symposium, Benvenuti, Sponsored by Formenti, Published by Minerva Medica, 1982; 59-70.&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Gibbins FJ, Lewis AM, Kesar DK</AU>
<TI>Effectiveness and safety of dantrolene sodium in comparison with baclofen in spasticity from multiple sclerosis. Cross-over study</TI>
<SO>Dantrolene sodium: New therapeutic approach to clinical problems of spasticity, Proceedings of the International Symposium</SO>
<YR>1982</YR>
<PG>59-70</PG>
<PB>Minerva Medica</PB>
<CY>Benvenuti</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glass-1974" NAME="Glass 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Glass, A. and A. Hannah. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia, 1974. 12(3): p. 170-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glass A, Hannah A</AU>
<TI>A comparison of dantrolene sodium and diazepam in the treatment of spasticity</TI>
<SO>Paraplegia</SO>
<YR>1974</YR>
<VL>12</VL>
<NO>3</NO>
<PG>170-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gobel-1999" NAME="Gobel 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gobel H, Schmid J, Heinze A, Pergande G</AU>
<TI>Reduction of spastic increased muscle tone in multiple sclerosis by the non-opioid analgesic flupirtine</TI>
<SO>Schmerz</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>5</NO>
<PG>324-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonsette-1978" NAME="Gonsette 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Gonsette, R.E., T. Capart, and L. Demonty. [Clinical study of sodium dantroline (Dantrium) in multiple sclerosis]. Acta Neurologica Belgica, 1978. 78(3): p. 141-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonsette RE, Capart T, Demonty L</AU>
<TI>[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis] [French]</TI>
<SO>Acta Neurologica Belgica</SO>
<YR>1978</YR>
<VL>78</VL>
<NO>3</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hassan-1980" NAME="Hassan 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Hassan, N. and D.L. McLellan. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1980. 43(12): p. 1132-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hassan N, McLellan DL</AU>
<TI>Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1980</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heazlewood-1983" NAME="Heazlewood 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Heazlewood, V., et al. Tizanidine--initial pharmacokinetic studies in patients with spasticity. European Journal of Clinical Pharmacology, 1983. 25(1): p. 65-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heazlewood V, Symoniw P, Maruff P, Eadie MJ</AU>
<TI>Tizanidine - initial pharmacokinetic studies in patients with spasticity</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>25</VL>
<NO>1</NO>
<PG>65-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedley-1975" NAME="Hedley 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Hedley, D., J. Maroun, and M. Espir. Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgraduate Medical Journal, 1975. 51(599): p. 615-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hedley DV, Maroun JA, Espir ML</AU>
<TI>Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1975</YR>
<VL>51</VL>
<NO>599</NO>
<PG>615-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herman-1992" NAME="Herman 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Herman, R., S. D'Luzansky, and R. Ippolito. Intrathecal baclofen suppresses central pain in patients with spinal lesions. The Clinical Journal of Pain, 1992. 8: p. 338-45.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herman R, D'Luzansky SC, Ippolito R</AU>
<TI>Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study</TI>
<SO>The Clinical Journal of Pain</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>4</NO>
<PG>338-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoogstraten-1988" NAME="Hoogstraten 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Hoogstraten, M.C., et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurologica Scandinavica, 1988. 77(3): p. 224-30.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoogstraten MC, van der Ploeg RJ, vd Burg W, Vreeling A, van Marle S, Minderhoud JM</AU>
<TI>Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1988</YR>
<VL>77</VL>
<NO>3</NO>
<PG>224-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hudgson-1971" NAME="Hudgson 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Hudgson, P., D. Weightman, and N.E. Cartlidge. Clinical trial of baclofen against placebo. Postgraduate Medical Journal, 1972. 48:Suppl(5): p. 37-40.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hudgson P, Weightman D, Cartlidge NE</AU>
<TI>Clinical trial of baclofen against placebo</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1972</YR>
<VL>48</VL>
<NO>Suppl 5</NO>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hudgson, P. and D. Weightman. Baclofen in the treatment of spasticity. British Medical Journal, 1971. 4(778): p. 15-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hudgson P, Weightman D</AU>
<TI>Baclofen in the treatment of spasticity</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>4</VL>
<NO>778</NO>
<PG>15-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huffman-1973" NAME="Huffman 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Huffmann, G., K. Fasshauer, and R. Giesen. [Effects of lioresal in therapy of spastic paralysis]. Medizinische Klinik, 1973. 68(11): p. 340-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huffmann G, Fasshauer K, Giesen R</AU>
<TI>[Effects of Lioresal in therapy of spastic paralysis] [German]</TI>
<SO>Medizinische Klinik</SO>
<YR>1973</YR>
<VL>68</VL>
<NO>11</NO>
<PG>340-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hugenholtz-1992" NAME="Hugenholtz 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Hugenholtz, H., et al. Intrathecal baclofen for intractable spinal spasticity - a double-blind crossover comparison with placebo in 6 patients. Canadian Journal of Neurological Sciences, 1992. 19(2): p. 188-95.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hugenholtz H, Nelson RF, Dehoux E, Bickerton R</AU>
<TI>Intrathecal baclofen for intractable spinal spasticity. A double-blind crossover comparison with placebo in 6 patients</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>2</NO>
<PG>188-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jabbari-1995" NAME="Jabbari 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Jabbari, B., et al. Botulinum toxin A effectiveness against spasticity and muscle spasms. Archives of Physical Medicine &amp;amp; Rehabilitation, 1995. 76: p. 1063 (abstr).&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jabbari B, et al</AU>
<TI>Botulinum toxin A effectiveness against spasticity and muscle spasms</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1995</YR>
<VL>76</VL>
<PG>1063 (abstr)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jabbari-1996" NAME="Jabbari 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Jabbari, B., K. Polo, and G. Ford. Longterm effects of botulinum toxin A in spasticity and rigidity. Movement Disorders, 1996. 11(Suppl Abstract P884): p. 234.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jabbari B, Polo K, Ford G</AU>
<TI>Longterm effects of botulinum toxin A in spasticity and rigidity</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Suppl Abstract P884</NO>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarrett-2002" NAME="Jarrett 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jarrett L, Nandi P, Thompson AJ</AU>
<TI>Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>6</NO>
<PG>705-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jerusalem-1968" NAME="Jerusalem 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Jerusalem, F. Doppeltblindstudie uber den antispastischen effekt von B-(4-chlorphenyl)-G-aminobuttersaure (CIBA) bei Multipler Sklerose. Der Nervenarzt, 1968. 39: p. 515-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jerusalem F</AU>
<TI>[Double-blind study of the antispastic effect of Beta-(4-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis</TI>
<TO>Doppeltblindstudie uber den antispastischen effekt von B-(4-chlorphenyl)-G-aminobuttersaure (CIBA) bei Multipler Sklerose</TO>
<SO>Der Nervenarzt</SO>
<YR>1968</YR>
<VL>39</VL>
<NO>11</NO>
<PG>515-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1976" NAME="Jones 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Jones, R. and J. Lance. Baclofen (Lioresal) in the long-term management of spasticity. Medical Journal of Australia, 1976. 1: p. 654-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jones R, Lance J</AU>
<TI>Baclofen (Lioresal) in the long-term management of spasticity</TI>
<SO>Medical Journal of Australia</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>18</NO>
<PG>654-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joynt-1976" NAME="Joynt 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Joynt, R. Dantrolene sodium: long-term effects in patients with muscle spasticity. Archives of Physical Medicine &amp;amp; Rehabilitation, 1976. 57: p. 212.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joynt RL</AU>
<TI>Dantrolene sodium: long-term effects in patients with muscle spasticity</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1976</YR>
<VL>57</VL>
<NO>5</NO>
<PG>212-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Keenan-1977" NAME="Keenan 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Keenan, R., M. Kolb, and M. Horne. Collaborative comparison of dantrolene sodium and diazepam in management of chronic spasticity after CNS lesions. Clinical Therapeutics, 1977. 1(1): p. 48-55.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keenan R, Kolb M, Horne M</AU>
<TI>Collaborative comparison of dantrolene sodium and diazepam in management of chronic spasticity after CNS lesions</TI>
<SO>Clinical Therapeutics</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>1</NO>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerty-1997" NAME="Kerty 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Kerty, E. and R. Stien. [Treatment of spasticity with botulinum toxin]. Tidsskrift for Den Norske Laegeforening, 1997. 117(14): p. 2022-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kerty E, Stien R</AU>
<TI>[Treatment of spasticity with botulinum toxin] [Norvegian]</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1997</YR>
<VL>117</VL>
<NO>14</NO>
<PG>2022-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ketelaer-1973" NAME="Ketelaer 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Ketelaer, P., J. Tyberghein, and C. Ketelaer. Lioresal in the treatment of increased muscle tone associated with multiple sclerosis. Brux Med, 1973. 53: p. 675-81.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ketelaer P, Tyberghein JM, Ketelaer CJ</AU>
<TI>[C34.647-Ba (Lioresal) in the treatment of hypertonic manifestation of multiple sclerosis] [French]</TI>
<SO>Bruxelles Medical</SO>
<YR>1973</YR>
<VL>53</VL>
<NO>11</NO>
<PG>675-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-1995" NAME="Khan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Khan, O.A. and M.J. Olek. Clonidine in the treatment of spasticity in patients with multiple sclerosis [letter]. Journal of Neurology, 1995. 242(10): p. 712-3.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khan OA, Olek MJ</AU>
<TI>Clonidine in the treatment of spasticity in patients with multiple sclerosis [letter]</TI>
<SO>Journal of Neurology</SO>
<YR>1995</YR>
<VL>242</VL>
<NO>10</NO>
<PG>712-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knutsson-1982" NAME="Knutsson 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Knutsson, E., A. Martensson, and L. Gransberg. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. Journal of the Neurological Sciences, 1982. 53(2): p. 187-204.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Knutsson E, Martensson A, Gransberg L</AU>
<TI>Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1982</YR>
<VL>53</VL>
<NO>2</NO>
<PG>187-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kravitz-1992" NAME="Kravitz 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kravitz, H., et al. Intrathecal baclofen: effects on nocturnal leg muscle spasticity. American Journal of Physical Medicine &amp;amp; Rehabilitation, 1992. 71(1): p. 48-52.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kravitz HM, Corcos DM, Hansen G, Penn RD, Cartwright RD, Gianino J</AU>
<TI>Intrathecal baclofen: effects on nocturnal leg muscle spasticity</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>1992</YR>
<VL>71</VL>
<NO>1</NO>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladd_x0028_1_x0029_-1974" NAME="Ladd(1) 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Ladd, H.W., et al. [Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity]. Union Medicale du Canada, 1973. 102(5): p. 1087-92.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ladd HW, Gingras G, Boucher J, Kazdan N, Keenan R</AU>
<TI>[Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity] [French]</TI>
<SO>Union Medicale du Canada</SO>
<YR>1973</YR>
<VL>102</VL>
<NO>5</NO>
<PG>1087-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladd_x0028_2_x0029_-1974" NAME="Ladd(2) 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Ladd, H., C. Oist, and B. Jonsson. The effect of Dantrium on spasticity in multiple sclerosis. Acta Neurologica Scandinavica, 1974. 50(4): p. 397-408.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ladd H, Oist C, Jonsson B</AU>
<TI>The effect of Dantrium on spasticity in multiple sclerosis</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1974</YR>
<VL>50</VL>
<NO>4</NO>
<PG>397-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Latash-1989" NAME="Latash 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Latash, M.L., et al. Short-term effects of intrathecal baclofen in spasticity. Experimental Neurology, 1989. 103(2): p. 165-72.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Latash ML, Penn RD, Corcos DM, Gottlieb GL</AU>
<TI>Short-term effects of intrathecal baclofen in spasticity</TI>
<SO>Experimental Neurology</SO>
<YR>1989</YR>
<VL>103</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazorthes-1990" NAME="Lazorthes 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Lazorthes, Y., et al. Chronic intrathecal baclofen administration for control of severe spasticity. Journal of Neurosurgery, 1990. 72(3): p. 393-402.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lazorthes Y, Sellerin-Caute B, Verdie JC, Bastide R, Carillo JP</AU>
<TI>Chronic intrathecal baclofen administration for control of severe spasticity</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1990</YR>
<VL>72</VL>
<NO>3</NO>
<PG>393-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1993" NAME="Lee 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lee, A. and V. Patterson. A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurologica Scandinavica, 1993. 88(5): p. 334-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee A, Patterson V</AU>
<TI>A double-blind study of L-threonine in patients with spinal spasticity</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>5</NO>
<PG>334-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1994" NAME="Lee 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Lee, J., et al., Results of a prospective randomized trial of botulinum toxin therapy in acute unilateral sixth nerve palsy. J Pediatr Ophthalmol Strabismus, 1994. 31: p. 283-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee J, Harris SS, Cohen J, Cooper K, MacEwen C, Jones S</AU>
<TI>Results of a prospective randomized trial of botulinum toxin therapy in acute unilateral sixth nerve palsy</TI>
<SO>Journal of Pediatric Ophthalmology &amp; Strabismus</SO>
<YR>1994</YR>
<VL>31</VL>
<NO>5</NO>
<PG>283-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leveghi--1998" NAME="Leveghi  1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Leveghi D, Corona AM, Bortolotti P (1998). Intrathecal baclofen efficacy in severe spasticity: medical rehabilitative management and follow-up. Rivista di Neurobiologia 44: 5; 499-503.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leveghi D, Corona AM, Bortolotti P</AU>
<TI>Intrathecal baclofen efficacy in severe spasticity: medical rehabilitative management and follow-up</TI>
<SO>Rivista di Neurobiologia</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>5</NO>
<PG>499-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1968" NAME="Levine 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Levine, I., et al. Prazepam in the treatment of spasticity. A quantitative double-blind evaluation. Neurology, 1969. 19: p. 510-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine IM, Jossmann PB, Friend DG, De Angelis V</AU>
<TI>Prazepam in the treatment of spasticity. A quantitative double-blind evaluation</TI>
<SO>Neurology</SO>
<YR>1969</YR>
<VL>19</VL>
<NO>5</NO>
<PG>510-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1969" NAME="Levine 1969" YEAR="1969">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine IM, Jossmann PB, Friend DG, DeAngelis V, Kane M</AU>
<TI>Diazepam in the treatment of spasticity</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1969</YR>
<VL>22</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine_x0028_1_x0029_-1977" NAME="Levine(1) 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Levine, I.M., et al. The quantitative evaluation of intravenous methocarbamol in the relief of spasticity. Neurology, 1968. 18(1 Pt 1): p. 69-74.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine IM, Jossmann PB, Rudd J, De Angelis V</AU>
<TI>The quantitative evaluation of intravenous methocarbamol in the relief of spasticity</TI>
<SO>Neurology</SO>
<YR>1968</YR>
<VL>1</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine_x0028_2_x0029_-1977" NAME="Levine(2) 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Levine, M. and J. Van Brocklin. Lioresal (baclofen) treatment of spasticity: a double-blind comparison study with dantrolene. Neurology, 1977. 27: p. 391.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levine M, Van Brocklin J</AU>
<TI>Lioresal (baclofen) treatment of spasticity: a double-blind comparison study with dantrolene</TI>
<SO>Neurology</SO>
<YR>1977</YR>
<VL>27</VL>
<PG>391</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Link-1999" NAME="Link 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Not RCT&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Link A, Kabus C, Haas J</AU>
<TI>Use of spasmography to assess the effects of botulinum toxin type A in patients with lower-limb spasticity</TI>
<SO>European Journal of Neurology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>Supplement 4</NO>
<PG>S69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lossius-1985" NAME="Lossius 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Lossius, R., P. Dietrichson, and P.K. Lunde. Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations. Acta Neurologica Scandinavica, 1985. 71(3): p. 190-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lossius R, Dietrichson P, Lunde PK</AU>
<TI>Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1985</YR>
<VL>71</VL>
<NO>3</NO>
<PG>190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loubser-1991" NAME="Loubser 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Loubser, P., et al. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia, 1991. 29: p. 48-64.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loubser PG, Narayan RK, Sandin KJ, Donavan WH, Russell KD</AU>
<TI>Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury</TI>
<SO>Paraplegia</SO>
<YR>1991</YR>
<VL>29</VL>
<NO>1</NO>
<PG>48-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mai-1979" NAME="Mai 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Mai, J. and E. Pedersen. Mode of action of dantrolene sodium in spasticity. Acta Neurologica Scandinavica, 1979. 59(6): p. 309-16.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mai J, Pedersen E</AU>
<TI>Mode of action of dantrolene sodium in spasticity</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>6</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayer-1973" NAME="Mayer 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Mayer, N., S. Mecomber, and R. Herman. Treatment of spasticity with dantrolene sodium. American Journal of Physical Medicine, 1973. 52(1): p. 18-29.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mayer N, Necomber SA, Herman R</AU>
<TI>Treatment of spasticity with dantrolene sodium</TI>
<SO>American Journal of Physical Medicine</SO>
<YR>1973</YR>
<VL>52</VL>
<NO>1</NO>
<PG>18-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Medici-1985" NAME="Medici 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Medici, M., M. Pebet, and C. Perez Zeinal. Tizanidine in the treatment of spasticity. A long term study (abstract no. 20.21.02). Journal of Neurology, 1985. 235(Suppl): p. 305.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Medici M, Pebet M, Perez Zeinal C</AU>
<TI>Tizanidine in the treatment of spasticity. A long term study (abstract no. 20.21.02)</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>235</VL>
<NO>Suppl</NO>
<PG>305</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Medici, M. A comparative trial of tizanidine and baclofen in patients with spasticity due to various neurological disorders (study No 39), Unpublished Sandoz Research Report.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Medici, M</AU>
<TI>A comparative trial of tizanidine and baclofen in patients with spasticity due to various neurological disorders (study No 39)</TI>
<SO>Unpublished Sandoz Research Report</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meinck-1989" NAME="Meinck 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Meinck, H.M., P.W. Schonle, and B. Conrad. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of Neurology, 1989. 236(2): p. 120-2.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meinck HM, Schonle PW, Conrad B</AU>
<TI>Effect of cannabinoids on spasticity and ataxia in multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1989</YR>
<VL>236</VL>
<NO>2</NO>
<PG>120-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyler-1981" NAME="Meyler 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Meyler, W.J., et al. The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1981. 44(4): p. 334-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyler WJ, Bakker H, Kok JJ, Agoston S, Wesseling H</AU>
<TI>The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1981</YR>
<VL>44</VL>
<NO>4</NO>
<PG>334-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mondrup-1983" NAME="Mondrup 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Mondrup, K. and E. Pedersen. The acute effect of the GABA-agonist, THIP, on proprioceptive and flexor reflexes in spastic patients. Acta Neurologica Scandinavica, 1983. 67(1): p. 48-54.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mondrup K, Pedersen E</AU>
<TI>The acute effect of the GABA-agonist, THIP, on proprioceptive and flexor reflexes in spastic patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>1</NO>
<PG>48-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mondrup-1984" NAME="Mondrup 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Mondrup, K. and E. Pedersen. The clinical effect of the GABA-agonist, progabide, on spasticity. Acta Neurologica Scandinavica, 1984. 69(4): p. 200-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mondrup K, Pedersen E</AU>
<TI>The clinical effect of the GABA-agonist, progabide, on spasticity</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1984</YR>
<VL>69</VL>
<NO>4</NO>
<PG>200-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monster-1973" NAME="Monster 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Monster, A., et al. Cooperative study for assessing the effects of a pharmacological agent on spasticity. American Journal of Physical Medicine, 1973. 52(4): p. 163-88.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Monster AW, Herman R, Meek SS, McHenry J</AU>
<TI>Cooperative study for assessing the effects of a pharmacological agent on spasticity</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>1973</YR>
<VL>52</VL>
<NO>4</NO>
<PG>163-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monster-1974" MODIFIED="2008-07-02 11:49:30 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Monster 1974" YEAR="1974">
<REFERENCE MODIFIED="2008-07-02 11:49:30 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Monster, AW</AU>
<TI>Spasticity and the effect of dantrolene sodium</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1974</YR>
<VL>55</VL>
<PG>373-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morita-2001" NAME="Morita 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morita H, Crone C, Christenhuis D, Petersen NT, Nielsen JB</AU>
<TI>Modulation of presynaptic inhibition and disynaptic reciprocal Ia inhibition during voluntary movement in spasticity</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>Pt 4</NO>
<PG>826-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1997" NAME="Mueller 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Mueller, M.E., et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Archives of Physical Medicine &amp;amp; Rehabilitation, 1997. 78(5): p. 521-4.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mueller ME, Gruenthal M, Olson WL, Olson WH</AU>
<TI>Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>5</NO>
<PG>521-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1987" NAME="Muller 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Muller, H., et al. The effect of intrathecal baclofen on electrical muscle activity in spasticity. Journal of Neurology, 1987. 234(5): p. 348-52.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller H, Zierski J, Dralle D, Borner U, Hoffmann O</AU>
<TI>The effect of intrathecal baclofen on electrical muscle activity in spasticity</TI>
<SO>Journal of Neurology</SO>
<YR>1987</YR>
<VL>234</VL>
<NO>5</NO>
<PG>348-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mutani-1971" NAME="Mutani 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Mutani, R., et al. [Kinetometric demonstration of the antispastic action of a GABA derivative (Ciba 34647-BA)]. Rivista di Neurologia, 1971. 41(3): p. 143-51.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mutani R, Fariello R, Quattrocolo G, Delsedime M</AU>
<TI>[Kinetometric demonstration of the antispastic action of a GABA derivative (Ciba 34647-BA)] [Italian]</TI>
<SO>Rivista di Neurologia</SO>
<YR>1971</YR>
<VL>41</VL>
<NO>3</NO>
<PG>143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nance-1995" NAME="Nance 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Nance P., et al. Intrathecal baclofen treatment for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Canadian Journal of Neurological Sciences, 1995. 22: p. 22-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer RD</AU>
<TI>Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>1</NO>
<PG>22-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nance-1997" NAME="Nance 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Nance, P., et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Archives of Neurology, 1997. 54(6): p. 731-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al</AU>
<TI>Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>6</NO>
<PG>731-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neretin-1978" NAME="Neretin 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Neretin, V., V.A. Kir'iakov, and L.N. Pegova. [Experience using sinakten-retard in the treatment of muscular sclerosis]. Zhurnal Nevropatologii i Psikhiatrii Imeni S - S - Korsakova, 1978. 78(4): p. 514-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neretin VI, Kir'iakov VA, Pegova LN</AU>
<TI>[Experience using sinakten-retard in the treatment of muscular sclerosis] [Russian]</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S - S - Korsakova</SO>
<YR>1978</YR>
<VL>78</VL>
<NO>4</NO>
<PG>514-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newman-1982" NAME="Newman 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Newman, P. A double-blind, comparative trial of tizanidine and baclofen in the treatment of chronic spasticity in patients with multiple sclerosis (study No 27). 1981, Unpublished Sandiz Research Report.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Newman P</AU>
<TI>A double-blind, comparative trial of tizanidine and baclofen in the treatment of chronic spasticity in patients with multiple sclerosis (study No 27)</TI>
<SO>Unpublished Sandoz Research Report</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Newman, P., et al. Tizanidine in the treatment of spasticity. European Journal of Clinical Pharmacology, 1982. 23: p. 31-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Newman PM, Nogues M, Newnam PK, Weighman D, Hudson P</AU>
<TI>Tizanidine in the treatment of spasticity</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>23</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen_x0028_1_x0029_-2000" NAME="Nielsen(1) 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Not RCT&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen JF, Anderson JB, Sinkjaer T</AU>
<TI>Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients</TI>
<SO>Multiple Sclerosis</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>2</NO>
<PG>105-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen_x0028_2_x0029_-2000" NAME="Nielsen(2) 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Not RCT&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen JF, Sinkjaer T</AU>
<TI>Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>1</NO>
<PG>98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ochs-1989" NAME="Ochs 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Ochs, G., et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study [see comments]. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1989. 52(8): p. 933-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J, Gardner BP, et al</AU>
<TI>Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1989</YR>
<VL>52</VL>
<NO>8</NO>
<PG>933-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ordia-1996" NAME="Ordia 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Ordia J., et al. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. Journal of Neurosurgery, 1996. 85: p. 452-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ordia JI, Fischer E, Adamski E, Spatz EL</AU>
<TI>Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>3</NO>
<PG>452-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orsnes_x0028_1_x0029_-2000" NAME="Orsnes(1) 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Not RCT&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Orsnes G, Crone C, Krarup C, Petersen N, Nielsen J</AU>
<TI>The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2000</YR>
<VL>111</VL>
<NO>8</NO>
<PG>1372-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orsnes_x0028_2_x0029_-2000" NAME="Orsnes(2) 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Not RCT&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Orsnes GB, Sorensen PS, Larsen TK, Ravnborg M</AU>
<TI>Effect of baclofen on gait in spastic MS patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>4</NO>
<PG>244-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagano-1988" NAME="Pagano 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Pagano, M., M. Ferreiro, and E. Herskovits. Comparative study of tizanidine and baclofen in patients with chronic spasticity. Rev Neurol Argent, 1988. 14(4): p. 268-76.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pagano M, Ferreiro M, Herskovits E</AU>
<TI>Comparative study of tizanidine and baclofen in patients with chronic spasticity</TI>
<SO>Revista Neurologica Argentina</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>4</NO>
<PG>268-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parke-1989" NAME="Parke 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Parke, B., et al. Functional outcome after delivery of intrathecal baclofen. Archives of Physical Medicine &amp;amp; Rehabilitation, 1989. 70(1): p. 30-2.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parke B, Penn RD, Savoy SM, Corcos D</AU>
<TI>Functional outcome after delivery of intrathecal baclofen</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1989</YR>
<VL>70</VL>
<NO>1</NO>
<PG>30-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1994" NAME="Patterson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Patterson, V., et al. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry, 1994. 57(5): p. 582-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Patterson V, Watt M, Byrnes D, Crowe D, Lee A</AU>
<TI>Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>5</NO>
<PG>582-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pederson-1970" NAME="Pederson 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Pederson, E., et al. GABA derivative in spasticity. Acta Neurologica Scandinavica, 1970. 46: p. 257-66.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pederson E, Arlien-Soborg P, Grynderup V, Henriksen O</AU>
<TI>GABA derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobulyric acid, Ciba 34.647-Ba)</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1970</YR>
<VL>46</VL>
<NO>3</NO>
<PG>257-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pederson-1981" NAME="Pederson 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Pedersen, E., H. Hansen, and J. Poulsen. Effect of symptomatiic therapy on motor difficulties in multiple sclerosis recorded by quantitative measurements of voluntary power. Acta Neurologica Scandinavica, 1981. 64: p. 253-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen E, Hansen HJ, Poulsen J</AU>
<TI>Effect of symptomatic therapy on motor difficulties in quantitative measurements of voluntary power</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1981</YR>
<VL>64</VL>
<NO>4</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penders-1976" NAME="Penders 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Penders, D., et al. Trial of a new muscle relaxant in the treatment of multiple sclerosis: dantrolene sodium. Ars Medici (Nivelles), 1976. 31(2): p. 331-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penders D, et al</AU>
<TI>Trial of a new muscle relaxant in the treatment of multiple sclerosis: dantrolene sodium</TI>
<SO>Ars Medici (Nivelles)</SO>
<YR>1976</YR>
<VL>31</VL>
<NO>2</NO>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penn-1985" NAME="Penn 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Penn, R. and J. Kroin. Continuous intrathecal baclofen for severe spasticity. Lancet, 1985. 7: p. 125-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penn Rd, Kroin Js</AU>
<TI>Continuous intrathecal baclofen for severe spasticity</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>8447</NO>
<PG>125-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penn-1989" NAME="Penn 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Penn, R.D., et al. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine, 1989. 320(23): p. 1517-21.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al</AU>
<TI>Intrathecal baclofen for severe spinal spasticity</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>23</NO>
<PG>1517-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penn-1992" NAME="Penn 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Penn, R. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. Journal of Neurosurgery, 1992. 77(2): p. 236-40.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penn RD</AU>
<TI>Intrathecal baclofen for spasticity of spinal origin: seven years of experience</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1992</YR>
<VL>77</VL>
<NO>2</NO>
<PG>236-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perkin-1976" NAME="Perkin 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Perkin, G. and M. Aminoff. A trial of brolitene in the treatment of spasticity. British Journal of Clinical Pharmacology, 1976. 3: p. 879-882.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perkin GD, Aminoff MJ</AU>
<TI>A trial of brolitene in the treatment of spasticity</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>3</VL>
<NO>5</NO>
<PG>879-882</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petro-1980" NAME="Petro 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Petro, D. Marijuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics, 1980. 21: p. 81-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petro DJ</AU>
<TI>Marijuana as a therapeutic agent for muscle spasm or spasticity</TI>
<SO>Psychosomatics</SO>
<YR>1980</YR>
<VL>21</VL>
<NO>1</NO>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petro-1981" NAME="Petro 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Petro, D.J. and C. Ellenberger. Treatment of human spasticity with delta 9-tetrahydrocannabinol. Journal of Clinical Pharmacology, 1981. 21(8-9 Suppl): p. 413S-416S.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petro DJ, Ellenberger CJr</AU>
<TI>Treatment of human spasticity with delta 9-tetrahydrocannabinol</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>21</VL>
<NO>8-9 Suppl</NO>
<PG>413S-416S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polman-1994" NAME="Polman 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Polman, C., et al. 4-Aminopyridine in the treatment of patients with multiple sclerosis: Long-term efficacy and safety. Archives of Neurology, 1994. 51(3): p. 292-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Bertelsmann FW, Van Loenen Ac, Koetsier JC</AU>
<TI>4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety</TI>
<SO>Archives of Neurology</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>3</NO>
<PG>292-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porsasz-1981" NAME="Porsasz 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Porsasz, G. A Dantrium spasmusgatlo hatasanak klinikai vizsgalata sclerosis multiplexes betegekben. Ideggyogyaszati Szemle, 1981. 34: p. 330-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Porsasz G</AU>
<TI>Clinical study of Dantrium in spasticity due to multiple sclerosis</TI>
<TO>A Dantrium spasmusgatlo hatasanak klinikai vizsgalata sclerosis multiplexes betegekben</TO>
<SO>Ideggyogyaszati Szemle</SO>
<YR>1981</YR>
<VL>34</VL>
<PG>330-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reisner-1978" NAME="Reisner 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Reisner, H. [Pharmacological treatment of pathological increases in muscle tonus]. Wiener Medizinische Wochenschrift, 1978. 128(3): p. 57-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reisner H</AU>
<TI>[Pharmacological treatment of pathological increases in muscle tonus] [German]</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1978</YR>
<VL>128</VL>
<NO>3</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringwald-1977" NAME="Ringwald 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Ringwald, E., et al. Klinische Erfahrungen mit einem neurartigen Myotonolytikum (DS 103-282 Sandoz). Nervenarzt, 1977. 48: p. 355-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ringwald E, Campean SJ, Gerstenbrand F, Lorincz A, Lorincz P, Ludin HP</AU>
<TI>[Clinical experiences with a new muscle relaxant (DS103-282 Sandoz)] [German]</TI>
<TO>Klinische Erfahrungen mit einem neurartigen Myotonolytikum (DS 103-282 Sandoz)</TO>
<SO>Nervenarzt</SO>
<YR>1977</YR>
<VL>48</VL>
<NO>7</NO>
<PG>355-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodgers-1999" NAME="Rodgers 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers MM, Mulcare JA, King DL, Mathews T, Gupta S, Glaser RM</AU>
<TI>Gait characteristics of individuals with multiple sclerosis before and after a 6-month aerobic training program</TI>
<SO>Journal of Rehabilitation Research &amp; Development</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>3</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossier-2000" MODIFIED="2008-07-02 11:50:18 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Rossier 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-07-02 11:50:18 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossier P, Van Erven S, Wade DT</AU>
<TI>The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis</TI>
<SO>European Journal of Neurology</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>6</NO>
<PG>741-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roussan-1982" NAME="Roussan 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Roussan, M., C. Terrence, and G. Fromm. Baclofen vs. diazepam in the treatment of spasticity with long-term follow-up of baclofen therapy. Archives of Physical Medicine &amp;amp; Rehabilitation, 1982. 63: p. 503 (abstr).&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roussan M, Terrence C, Fromm G</AU>
<TI>Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1982</YR>
<VL>63</VL>
<PG>503 (abstr)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudick-1987" NAME="Rudick 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Rudick, R.A., D. Breton, and R.L. Krall. The GABA-agonist progabide for spasticity in multiple sclerosis. Archives of Neurology, 1987. 44(10): p. 1033-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rudick RA, Breton D, Krall RL</AU>
<TI>The GABA-agonist progabide for spasticity in multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1033-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltuari-1992" NAME="Saltuari 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Saltuari, L., et al. Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity. Acta Neurologica, 1992. 14(3): p. 187-94.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saltuari L, Kronenberg M, Marosi MJ, Kofler M, Russegger L, Rifici C, et al</AU>
<TI>Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity</TI>
<SO>Acta Neurologica</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>3</NO>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1991" MODIFIED="2008-08-22 09:59:59 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Smith 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Smith, C.R., et al. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology, 1991. 41(11): p. 1829-31.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith CR, La Rocca NG, Giesser BS, Scheinberg LC</AU>
<TI>High-dose oral baclofen: experience in patients with multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>11</NO>
<PG>1829-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1992" NAME="Smith 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Smith, M., et al. Baclofen effect on quadriceps strength in multiple sclerosis. Archives of Physical Medicine &amp;amp; Rehabilitation, 1992. 73: p. 237-40.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith MB, Brar SP, Nelson LM, Franklin GM, Cobble ND</AU>
<TI>Baclofen effect on quadriceps strength in multiple sclerosis</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1992</YR>
<VL>73</VL>
<NO>3</NO>
<PG>237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toste-1999" NAME="Toste 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Toste T, Balao F, Festas C, Pereira S, Marcal N (1999). Treatment of spasticity with intrathecal morphine in multiple sclerosis. Arquivos de Fisiatria e Doencas Osteo-Articulares 6: 2; 63-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Toste T, Balao F, Festas C, Pereira S, Marcal N</AU>
<TI>Treatment of spasticity with intrathecal morphine in multiple sclerosis</TI>
<SO>Arquivos de Fisiatria e Doencas Osteo-Articulares</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>2</NO>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ungerleider-1987" NAME="Ungerleider 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Ungerleider, J.T., et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in Alcohol &amp;amp; Substance Abuse, 1987. 7(1): p. 39-50.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW</AU>
<TI>Delta-9-THC in the treatment of spasticity associated with multiple sclerosis</TI>
<SO>Advances in Alcohol &amp; Substance Abuse</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Ouwenaller-1985" NAME="van Ouwenaller 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Van Ouwenaller, C. and A. Chantraine. A new myorelaxant in neurological affectations. Journal of Neurology, 1985. 235(Suppl): p. 305.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Ouwenaller C, Chantraine A</AU>
<TI>A new myorelaxant in neurological affectations</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>235</VL>
<NO>Suppl</NO>
<PG>305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verrier-1977" NAME="Verrier 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Verrier. Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity. Archives of Physical Medicine &amp;amp; Rehabilitation, 1977. 58(4): p. 148-53.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Verrier M, Ashby P, MacLeod S</AU>
<TI>Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>1977</YR>
<VL>58</VL>
<NO>4</NO>
<PG>148-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogt-2000" NAME="Vogt 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vogt T, Urban PP</AU>
<TI>Optimising therapy of spastic syndrome by combining intrathecal baclofen with botulinum toxin</TI>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>12</NO>
<PG>1007-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiser-1978" NAME="Weiser 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Weiser, R., et al. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. The Practitioner, 1978. 221: p. 123-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiser R, Terenty T, Hudgson P, Weightman D,</AU>
<TI>Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease</TI>
<SO>The Practitioner</SO>
<YR>1978</YR>
<VL>221</VL>
<NO>1321</NO>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wickstrom-1987" NAME="Wickstrom 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Wickstrom, J. A double-blind, parallel group, therapeutic comparative study to assess the efficacy and tolerability of tizanidine (Sirdalud) vs baclofen in the treatment of spasticity due to multiple sclerosis. 1987, Unpublished Sandoz Research Report.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Wickstrom J</AU>
<TI>A double-blind, parallel group, therapeutic comparative study to assess the efficacy and tolerability of tizanidine (Sirdalud) vs baclofen in the treatment of spasticity due to multiple sclerosis</TI>
<SO>Unpublished Sandoz Research Report</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1966" NAME="Wilson 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Wilson, L. and A. McKechnie. Oral diazepam in the treatment of spasticity in paraplegia: a double-blind trial and subsequent impressions. Scot Med J, 1966. 11: p. 46-51.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilson LA, McKechnie AA</AU>
<TI>Oral diazepam in the treatment of spasticity in paraplegia: a double-blind trial and subsequent impressions</TI>
<SO>Scottish Medical Journal</SO>
<YR>1966</YR>
<VL>11</VL>
<NO>2</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-22 10:01:25 +0200" MODIFIED_BY="Deirdre Beecher">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-22 10:01:25 +0200" MODIFIED_BY="Deirdre Beecher">
<REFERENCE ID="REF-Ashworth-1964" MODIFIED="2008-07-01 12:03:10 +0200" MODIFIED_BY="Liliana Coco" NAME="Ashworth 1964" TYPE="JOURNAL_ARTICLE">
<AU>Ashworth B</AU>
<TI>Preliminary trial of carisoprodol in multiple sclerosis</TI>
<SO>Practitioner</SO>
<YR>1964</YR>
<VL>192</VL>
<PG>540-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohannon-1987" MODIFIED="2008-07-01 12:03:25 +0200" MODIFIED_BY="Liliana Coco" NAME="Bohannon 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bohannon RW</AU>
<TI>Variability and reliability of the pendulum test for spasticity using a Cybex isokinetic dynamometer</TI>
<SO>Physical Therapy</SO>
<YR>1987</YR>
<VL>67</VL>
<NO>5</NO>
<PG>659-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1995" MODIFIED="2008-07-01 12:03:47 +0200" MODIFIED_BY="Liliana Coco" NAME="Clarke 1995" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Establishing and maintaining an international register of RCTs. Cochrane Reviewers' Handbook</TI>
<SO>In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haber-1985" MODIFIED="2008-07-01 12:03:58 +0200" MODIFIED_BY="Liliana Coco" NAME="Haber 1985" TYPE="BOOK">
<AU>Haber A, LaRocca N (eds)</AU>
<SO>Minimal record of disability for multiple sclerosis</SO>
<YR>1985</YR>
<PB>National Multiple Sclerosis Society</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" MODIFIED="2008-07-01 12:04:09 +0200" MODIFIED_BY="Liliana Coco" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lance-1980" MODIFIED="2008-07-01 12:04:17 +0200" MODIFIED_BY="Liliana Coco" NAME="Lance 1980" TYPE="CONFERENCE_PROC">
<AU>Lance JW</AU>
<TI>Symposium synopsis</TI>
<SO>Spasticity: disordered motor control</SO>
<YR>1980</YR>
<PG>485-94</PG>
<ED>De Feldman RG, Young RR, Koella WP</ED>
<PB>Symposia Specialists</PB>
<CY>Miami</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandyan-1999" MODIFIED="2008-07-01 12:04:40 +0200" MODIFIED_BY="Liliana Coco" NAME="Pandyan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H</AU>
<TI>A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>5</NO>
<PG>373-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perry-1993" MODIFIED="2008-07-01 12:05:32 +0200" MODIFIED_BY="Liliana Coco" NAME="Perry 1993" TYPE="JOURNAL_ARTICLE">
<AU>Perry J</AU>
<TI>Determinants of muscle function in the spastic lower extremity</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1993</YR>
<VL>288</VL>
<PG>10-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" MODIFIED="2008-07-01 12:06:08 +0200" MODIFIED_BY="Liliana Coco" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al</AU>
<TI>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wade-1992" MODIFIED="2008-07-01 12:06:13 +0200" MODIFIED_BY="Liliana Coco" NAME="Wade 1992" TYPE="BOOK">
<AU>Wade DT</AU>
<SO>Measurement in neurological rehabilitation</SO>
<YR>1992</YR>
<PB>Oxford Medical Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallace-1994" MODIFIED="2008-07-01 12:06:16 +0200" MODIFIED_BY="Liliana Coco" NAME="Wallace 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wallace JD</AU>
<TI>Summary of combined clinical analysis of controlled clinical trials with tizanidine</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>11 Suppl 9</NO>
<PG>S60-8; discussion S68-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1994" MODIFIED="2008-07-01 12:06:21 +0200" MODIFIED_BY="Liliana Coco" NAME="Whitehead 1994" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Jones NM</AU>
<TI>A meta-analysis of clinical trials involving different classifications of response into ordered categories</TI>
<SO>Statistics in Medicine</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>23-4</NO>
<PG>2503-15</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1974">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (dose not reported) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive stretch, range of motion, reflexes, clonus, associated movements, muscle power (clinically and by strain gauge), patellar reflex force, quadriceps EMG, patient self-report of spasms and function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1975">
<CHAR_METHODS>
<P>Crossover study (same methodology as Basmajian 1974)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 MS patients (8 patients previously reported in Basmajian 1974)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (dose not reported) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive stretch, range of motion, reflexes, clonus, associated movements, muscle power (clinically and by strain gauge), patellar reflex force, quadriceps EMG, patient self-report of spasms and function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1984">
<CHAR_METHODS>
<P>Crossover studies, with four arms comparing high and low doses of drugs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total 30 patients in the two studies (Basmajian 1984 &amp; 1986)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ketazolam (30mg &amp; 60mg) v. diazepam (15mg &amp; 30mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle tone &amp; power, range of motion, reflexes, clonus, associated movements, pain, spasms, subjective impression of level of function, patellar reflex force, quadriceps EMG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Basmajian-1986">
<CHAR_METHODS>
<P>see Basmajian1984 for combined summary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bass-1988">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>66 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 80mg) v. tizanidine (up to 32mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle tone &amp; power, EDSS score, Pedersen functional disability scale, reflexes, clonus, overall evaluations of efficacy and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bovier-1985">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS>
<P>Progabide v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES>
<P>Omitted from review as drug not used therapeutically</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brar-1991">
<CHAR_METHODS>
<P>Crossover study with 5 stages.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 patients with minimal to moderate spasticity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (20mg) or placebo, with and without an exercise programme.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth, Cybex II isokinetic unit, timed gait, patient questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chrzanowski-1981">
<CHAR_METHODS>
<P>Parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 MS patients aged 24-69</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 90mg) v. tizanidine (up to 36mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, spasm &amp; clonus score, functional assessment - no details reported for any of these assessments</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Eyssette-1988">
<CHAR_METHODS>
<P>Multi-centre, parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 patients aged 18-70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 60mg) v. tizanidine (up to 24mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Locomotor function, condition in bed &amp; chair, spasms, tonic stretch reflex, clonus, power, bladder control</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Feldman-1978">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 patients aged 38-53 with any degree of spasticity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 80mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Daily spasm count, resistance to passive movement, clonus, Barthel score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-From-1975">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 mostly non-ambulant patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 120mg) v. diazepam (up to 40mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, clonus, spasm score, walking ability, side-effects, physician's global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gelenberg-1973">
<CHAR_METHODS>
<P>Crossover trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 patients (14 ambulant)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dantrolene (up to 800mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive movement, clonus, reflexes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grazko-1995">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>5 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Botulinum toxin (dose estimated according to muscle size) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, spasm score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hauser-1992">
<CHAR_METHODS>
<P>Crossover trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 ambulant patients with spasticity or spasms which affected function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Threonine (7.5g) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth scale, EDSS score, Ambulation Index, combined clinical assessment scale, patient scale of three most troublesome symptoms, video gait analysis, H-reflex study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hyman-2000">
<CHAR_METHODS>
<P>Multi-centre, parallel-group, dose-ranging study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>74 patients with disabling thigh-adductor spasticity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Botulinum toxin (Dysport) 500, 1000 or 1500 MU v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Joint range of movement, total spasticity score (modified Ashworth score x spasm score), pain, hygiene, overall clinical impression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jellinger-1983">
<CHAR_METHODS>
<P>Cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 MS patients aged 18-70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tizanidine (up to 24mg, mean 14.8mg) v. diazepam (up to 30mg, mean 14.5mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Kurtzke EDSS, Pedersen functional assessment scale, global impression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Joder_x002d_Ohlenbusch-_x0027_84">
<CHAR_METHODS>
<P>Cross-over study (6 week treatment periods)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 patients, 25 with MS (individual patient data available)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vigabatrin 3 g daily v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, unvalidated spasm score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Killestein-2002">
<CHAR_METHODS>
<P>Cross-over study (4 week treatment periods)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2.5-5mg THC v. C. sativa plant extract v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, EDSS, MS Functional composite score (timed walk, 9 hole peg test, PASAT), MS Fatigue Severity Scale, SF36, visual analogue scales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lapierre-1987">
<CHAR_METHODS>
<P>Parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>66 patients aged 18-60, with spasticity severe enough to affect function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tizanidine (up to 36mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive stretch, muscle power, reflexes, clonus, EDSS score, ambulation index, upper extremities index, electrophysiological studies (including H-max/M-max)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Levine_x0028_1_x0029_-1969">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 mainly non-ambulant, paraplegic patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prazepam (5-25mg as tolerated) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EMG (spontaneous muscle activity, and response to electrical stimuli and gravity)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Luisto-1982">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Included 3 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dantrolene (up to 400mg daily) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Unvalidated spasticity scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pellkofer-1989">
<CHAR_METHODS>
<P>Parallel-group study lasting up to 35 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>47 MS patients with disabling lower limb spasticity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tetrazepam v. tizanidine v. baclofen (doses optimised but not reported)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EDSS, Ashworth scale, symptom reports, unvalidated 4-point scale of tolerability and 5-point scale of overall therapeutic effect</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rinne-1980">
<CHAR_METHODS>
<P>Parallel-group studies (two were excluded from the review as results for MS and non-MS patients could not be separated)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tizanidine (up to 18mg) v. diazepam (up to 22.5mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth score, overall tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sachais-1977">
<CHAR_METHODS>
<P>Parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>106 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (60-80mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive movement, spasms, degree of knee jerks, subjective patient report of spasms, clonus and function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sawa-1979">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 patients with lower limb spasticity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 60mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Time taken for passively flexed knee of a supine patient to fall on to the bed, spasms &amp; gait.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schmidt-1975">
<CHAR_METHODS>
<P>Crossover study, with four arms comparing low and high doses of drugs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 mainly ambulant patients with moderate to severe spasticity which affected function but without severe lower limb weakness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Diazepam (8mg and 20mg) v. dantrolene (100mg and 300 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle tone &amp; power, coordination, reflexes, clonus, walking-speed, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sheplan-1975">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 men</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dantrolene (up to 400mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive movement, clonus, reflexes, stretch reflex inhibition, H-reflex response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-1994">
<CHAR_METHODS>
<P>Multi-centre, parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>220 patients aged 18-70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tizanidine (2-36mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary end-points: Ashworth score, patient diaries (muscle spasm &amp; clonus scores). Secondary end-points: reflexes, clonus, spasms (assessed by physician), muscle power (MRC grade), walking time, ADL, global evaluation of efficacy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smolenski-1981">
<CHAR_METHODS>
<P>Parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 hospitalised patients aged 42-73</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 80mg) v. tizanidine (up to 36mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth scale, EDSS score, spasm score, muscle power, global impression, side-effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Snow-1990">
<CHAR_METHODS>
<P>Crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 severely-disabled patients with adductor spasticity inadequately treated on oral medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Botulinum toxin (supplied by Smith-Kettlewell Eye Research Institute, San Francisco) 400 MU v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle tone, spasm frequency, hygiene score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stien-1987">
<CHAR_METHODS>
<P>Parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 severely handicapped patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (up to 90mg) v. tizanidine (up to 36 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ashworth scale, EDSS, Pedersen rating scales, overall impression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tell-1981">
<CHAR_METHODS>
<P>Cross-over trial (duration of each arm 5-14 days)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 patients, 5 with MS (individual patient data available)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vigabatrin 2 g daily v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Unvalidated spasticity and spasm scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tolosa-1975">
<CHAR_METHODS>
<P>Parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 patients (11 wheelchair-bound)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dantrolene (up to 800mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Resistance to passive movement, reflexes, clonus</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UKTTG-1994">
<CHAR_METHODS>
<P>Multi-centre, parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>187 patients aged 18-75</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tizanidine (up to 36mg) v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome measure: Ashworth scale. Secondary measures: muscle power (MRC grade), EDSS score, reflexes, clonus, spasm score, 8m walking time, scales of intermediate motor skills and upper limb functions, ADL (Incapacity Status Scale), subjective assessments of overall effect on function, efficacy and tolerability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wade-2003">
<CHAR_METHODS>
<P>Crossover study with 2 week blocks, without intervening washout periods</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 patients with intractable neurogenic symptoms, 18 with MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THC v. CBD v. 1:1 mixture of THC:CBD v. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>daily patient visual analogue scales, Ashworth score, numerical investigator rating of symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wuthrich-1981">
<CHAR_METHODS>
<P>6 week parallel-group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 MS patients aged 19-71</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Baclofen (20-60mg) v. tizanidine (8-24mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>As Chrzanowski (1981)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: <BR/>Ashworth:<BR/>CBD: <BR/>Cybex II isokinetic unit: <BR/>EDSS:<BR/>EMG:<BR/>MRC grade: <BR/>PASAT:<BR/>THC: <BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abel-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azouvi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barat-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbeau-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Basmajian-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baykuschev-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Becker-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Behan-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergamini-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bianchi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Birkmayer-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bittencourt-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Broggi-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Broseta-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficent duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burke-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cartlidge-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Castaigne-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cendrowski_x0028_1_x0029_-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cendrowski_x0028_2_x0029_-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chantraine-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chipman-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chyatte-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coffey-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohan-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corston--1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cumming-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cutter-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dressnandt-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duncan-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dunevsky-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emre-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Finnimore-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fra-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gambi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerstenbrand-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gibbins-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No evidence of blinding in published report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glass-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gobel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gonsette-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hassan-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heazlewood-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hedley-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoogstraten-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-blind study only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hudgson-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huffman-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hugenholtz-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jabbari-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jabbari-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jarrett-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jerusalem-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joynt-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keenan-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kerty-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ketelaer-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knutsson-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kravitz-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ladd_x0028_1_x0029_-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ladd_x0028_2_x0029_-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Latash-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lazorthes-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCt of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leveghi--1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine_x0028_1_x0029_-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine_x0028_2_x0029_-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Link-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lossius-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loubser-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mai-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mayer-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Medici-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meinck-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meyler-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mondrup-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mondrup-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug not used therapeutically for toxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monster-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monster-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No details of patients' diagnoses. No validated outcome measure used. Unable to extract details of first crossover period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morita-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mueller-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mutani-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nance-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nance-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neretin-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newman-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielsen_x0028_1_x0029_-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielsen_x0028_2_x0029_-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ochs-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ordia-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orsnes_x0028_1_x0029_-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orsnes_x0028_2_x0029_-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pagano-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parke-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patterson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pederson-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pederson-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Penders-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Penn-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Penn-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Penn-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perkin-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug not used therapeutically for toxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petro-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petro-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polman-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Porsasz-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reisner-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ringwald-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodgers-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossier-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roussan-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rudick-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug not used therapeutically for toxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saltuari-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toste-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ungerleider-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Ouwenaller-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Verrier-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT of sufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vogt-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiser-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wickstrom-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to obtain further details of study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate data for non-MS patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Basmajian-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Basmajian-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Basmajian-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Basmajian-1986">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bass-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bovier-1985">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brar-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chrzanowski-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eyssette-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-From-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gelenberg-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Grazko-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hauser-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hyman-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jellinger-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Joder_x002d_Ohlenbusch-_x0027_84">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killestein-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Levine_x0028_1_x0029_-1969">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luisto-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pellkofer-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rinne-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sachais-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sawa-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sheplan-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smith-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smolenski-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Snow-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stien-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tell-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tolosa-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-UKTTG-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Wade-2003">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wuthrich-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-07-03 11:09:23 +0200" MODIFIED_BY="Liliana Coco">
<APPENDIX ID="APP-01" MODIFIED="2008-07-02 11:23:11 +0200" MODIFIED_BY="Deirdre Beecher" NO="1">
<TITLE MODIFIED="2008-07-02 09:40:33 +0200" MODIFIED_BY="Deirdre Beecher">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-02 11:23:11 +0200" MODIFIED_BY="Deirdre Beecher">
<P>#1"multiple sclerosis"<BR/>#2MeSH descriptor Multiple Sclerosis explode all trees<BR/>#3"transverse myelitis"<BR/>#4MeSH descriptor Myelitis, Transverse, this term only<BR/>#5"neuromyelitis optica"<BR/>#6"optic neuritis"<BR/>#7MeSH descriptor Optic Neuritis explode all trees<BR/>#8"encephalomyelitis acute disseminated"<BR/>#9MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only<BR/>#10"devic"<BR/>#11MeSH descriptor Muscle Spasticity explode all trees<BR/>#12MeSH descriptor Spasm explode all trees<BR/>#13spasticity<BR/>#14spasm<BR/>#15muscle NEXT spasticity<BR/>#16(#11 OR #12 OR #13 OR #14 OR 25)<BR/>#17MeSH descriptor Baclofen, this term only<BR/>#18MeSH descriptor Dantrolene explode all trees<BR/>#19MeSH descriptor Botulinum Toxins explode all trees<BR/>#20baclofen<BR/>#21dantrolene<BR/>#22tizanidine<BR/>#23gabapentin<BR/>#24botulinum NEXT toxin<BR/>#25(#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)<BR/>#26MeSH descriptor Vigabatrin, this term only<BR/>#27MeSH descriptor gamma-Aminobutyric Acid explode all trees<BR/>#28MeSH descriptor Diazepam explode all trees<BR/>#29vigabatrin<BR/>#30diazepam<BR/>#31ketazolam<BR/>#32(#26 OR #27 OR #28 OR #29 OR #30 OR #31)<BR/>#33MeSH descriptor Cannabinoids explode all trees<BR/>#34MeSH descriptor Aminopyridines explode all trees<BR/>#35cannabinoid*<BR/>#36cyproheptadine<BR/>#37progabide<BR/>#38oxcarbazepine<BR/>#39threonine<BR/>#40diaminopyridine<BR/>#41GABA<BR/>#42(#33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41)<BR/>#43(#16 AND ( #25 OR #32 OR #42 ))<BR/>#44MeSH descriptor Demyelinating Diseases, this term only<BR/>#45"demyelinating disease*"<BR/>#46(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #44 OR #45)<BR/>#47(#43 AND #46)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-07-02 10:33:19 +0200" MODIFIED_BY="Deirdre Beecher" NO="2">
<TITLE MODIFIED="2008-07-02 10:20:53 +0200" MODIFIED_BY="Deirdre Beecher">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-02 10:33:19 +0200" MODIFIED_BY="Deirdre Beecher">
<P>((("Muscle Spasticity"[Mesh]) OR ("Spasm"[Mesh]) OR (spasticity) OR (spasm) OR ("muscle spasticity")) AND ((("Baclofen"[Mesh]) OR ("Dantrolene"[Mesh]) OR ("Botulinum Toxins"[Mesh]) OR (baclofen) OR (dantrolene) OR (tizanidine) OR (gabapentin) OR ("botulinum toxin*")) OR (("Vigabatrin"[Mesh]) OR ("gamma-Aminobutyric Acid"[Mesh]) OR ("Diazepam"[Mesh]) OR (vigabatrin) OR (diazepam) OR (ketazolam)) OR (("Cannabinoids"[Mesh]) OR ("Aminopyridines"[Mesh]) OR (cannabinoid*) OR (cyproheptadine) OR (progabide) OR (oxcarbazepine) OR (threonine) OR (diaminopyridine) OR (GABA)))) AND (((("Multiple Sclerosis"[mh]) OR ("Myelitis, Transverse"[mh:noexp]) OR ("Demyelinating Diseases"[mh:noexp]) OR ("Encephalomyelitis, Acute Disseminated"[mh:noexp]) OR ("Optic Neuritis"[mh])) OR ((("multiple sclerosis") OR ("neuromyelitis optica") OR ("transverse myelitis") OR (encephalomyelitis) OR (devic) OR ("optic neuritis")) OR ("demyelinating disease*") OR ("acute disseminated encephalomyelitis"))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh])))))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-07-03 11:09:23 +0200" MODIFIED_BY="Liliana Coco" NO="3">
<TITLE MODIFIED="2008-07-02 10:21:04 +0200" MODIFIED_BY="Deirdre Beecher">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-03 11:09:23 +0200" MODIFIED_BY="Liliana Coco">
<P>((('encephalomyelitis'/exp) OR ('demyelinating disease'/exp) OR ('multiple sclerosis'/exp) OR ('myelooptic neuropathy'/exp) OR ('multiple sclerosis':ab,ti) OR ('neuromyelitis optica':ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ab,ti)) AND (('crossover procedure'/exp) OR ('double blind<B> </B>procedure'/exp) OR ('single blind procedure'/exp) OR ('randomized controlled trial'/exp) OR (random<B>*</B>:ab,ti) OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR (placebo*:ab,ti) OR ('double blind':ab,ti) OR ('single blind':ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti))) AND (('spasticity'/exp) OR ('muscle spasm'/exp) OR (spasticity:ab,ti) OR (spasm:ti,ab)) AND (('baclofen'/exp) OR ('dantrolene'/exp) OR ('botulinum toxin'/exp) OR (baclofen:ab,ti) OR (dantrolene:ab,ti) OR ('botulinum toxins':ab,ti) OR (tizanidine:ab,ti) OR (gabapentin:ab,ti) OR ('vigabatrin'/exp) OR (vigabatrin:ab,ti) OR ('4 aminobutyric acid'/exp) OR ('diazepam'/exp) OR (diazepam:ab,ti) OR (ketazolam:ab,ti) OR (cannabinoid*:ab,ti) OR ('cannabinoid'/exp) OR (cyproheptadine:ab,ti) OR (progabide:ab,ti) OR (oxcarbazepine:ab,ti) OR (threonine:ab,ti) OR (diaminopyridine:ab,ti) OR ('aminopyridine derivative'/exp) OR (gaba:ab,ti)) AND [humans]/lim AND [embase]/lim</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>